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most common childhood brain cancer. Despite favorable outcomes with surgical and adjuvant therapies,
majority of patients suffer from long-term treatment-related morbidities and recurrent/inoperable disease.
This necessitates a deeper understanding of PLGG biology to aid development of molecular diagnostics and
low-toxicity targeted therapeutics.
Hitherto, PLGGs have been defined by activating mutations that dysregulate the MAPK signaling pathway,
leading to clinical testing of RAF/MAPK inhibitors for PLGGs. Interestingly, recent large-scale sequencing
efforts discovered novel gene fusions in PLGGs and we identified the unique recurrent association of tumor
suppressor Quaking (QKI) with distinct proto-oncogenes, MYB and RAF1, in different PLGG sub-types. We
hypothesized that MYB-QKI and QKI-RAF1 function via novel oncogenic mechanisms invoking a two-hit
mechanism of gain-of-function in the MYB/RAF1 oncoproteins collaborating with QKI loss of putative
tumor suppressor function, describing for the first time a unique gene fusion setting involving both fusion
partners with implications for therapeutic targeting.
Utilizing heterologous cell model systems and in vivo mouse models, we found MYB-QKI and QKI-RAF1 are
capable of driving oncogenesis. Furthermore, MYB-QKI is a specific driver mutation defining angiocentric
gliomas and mediates tumorigenesis via a tri-partite mechanism: (1)MYB oncogenic activation via
truncation, (2)rearrangement led enhancer translocation that drives MYB-QKI expression and (3)LOH of
QKI tumor suppressor. In contrast, QKI-RAF1 drives some pilocytic astrocytomas via aberrant activation of
the MAPK pathway in a QKI-dimerization dependent manner. We also found differential response to RAF
targeted therapy in QKI-RAF1, compared to BRAF fusions in PLGGs, due to QKI-mediated dimerization.
Hence, our study highlights distinct roles for the same gene, QKI in supporting the oncogenic functions of
MYB and RAF1 in different PLGG-gene fusions.
Overall, our study has uncovered distinct molecular mechanisms associated with different QKI gene fusions
in PLGGs. We show that MYB-QKI is specific to angiocentric gliomas and mediates a unique oncogenic
program, and with QKI-RAF1 we demonstrate how mutational context guides differential response to
targeted therapy. Therefore, our study has important clinical implications on molecular diagnostics and
targeted therapy for these rather understudied class of childhood brain tumors.
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ABSTRACT 
 
MOLECULAR MECHANISMS OF ONCOGENESIS & PRECISION MEDICINE 
APPROACHES FOR PEDIATRIC LOW-GRADE GLIOMAS  
  Payal Jain 
Adam C. Resnick, PhD 
 
Pediatric low-grade gliomas (PLGGs) are a heterogeneous group of tumors that collectively 
represent the most common childhood brain cancer. Despite favorable outcomes with surgical 
and adjuvant therapies, majority of patients suffer from long-term treatment-related morbidities 
and recurrent/inoperable disease. This necessitates a deeper understanding of PLGG biology to 
aid development of molecular diagnostics and low-toxicity targeted therapeutics.  
 
Hitherto, PLGGs have been defined by activating mutations that dysregulate the MAPK signaling 
pathway, leading to clinical testing of RAF/MAPK inhibitors for PLGGs. Interestingly, recent 
large-scale sequencing efforts discovered novel gene fusions in PLGGs and we identified the 
unique recurrent association of tumor suppressor Quaking (QKI) with distinct proto-oncogenes, 
MYB and RAF1, in different PLGG sub-types. We hypothesized that MYB-QKI and QKI-RAF1 
function via novel oncogenic mechanisms invoking a two-hit mechanism of gain-of-function in the 
MYB/RAF1 oncoproteins collaborating with QKI loss of putative tumor suppressor function, 
describing for the first time a unique gene fusion setting involving both fusion partners with 
implications for therapeutic targeting.  
 
Utilizing heterologous cell model systems and in vivo mouse models, we found MYB-QKI and 
QKI-RAF1 are capable of driving oncogenesis. Furthermore, MYB-QKI is a specific driver 
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mutation defining angiocentric gliomas and mediates tumorigenesis via a tri-partite mechanism: 
(1)MYB oncogenic activation via truncation, (2)rearrangement led enhancer translocation that 
drives MYB-QKI expression and (3)LOH of QKI tumor suppressor. In contrast, QKI-RAF1 
drives some pilocytic astrocytomas via aberrant activation of the MAPK pathway in a QKI-
dimerization dependent manner. We also found differential response to RAF targeted therapy in 
QKI-RAF1, compared to BRAF fusions in PLGGs, due to QKI-mediated dimerization. Hence, our 
study highlights distinct roles for the same gene, QKI in supporting the oncogenic functions of 
MYB and RAF1 in different PLGG-gene fusions.  
Overall, our study has uncovered distinct molecular mechanisms associated with different QKI 
gene fusions in PLGGs. We show that MYB-QKI is specific to angiocentric gliomas and mediates 
a unique oncogenic program, and with QKI-RAF1 we demonstrate how mutational context guides 
differential response to targeted therapy. Therefore, our study has important clinical implications 
on molecular diagnostics and targeted therapy for these rather understudied class of childhood 
brain tumors.  
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CHAPTER 1: Introduction 
 
Pediatric Brain Cancer  
 
Childhood brain cancer is defined as a disease where abnormal cells accumulate in the tissues of 
the brain and spinal cord, which together make up the central nervous system (CNS). CNS tumors 
represent the most common cancer in children 0-14 years with infants (<1 year old) showing the 
highest brain tumor incidence of all children, even surpassing leukemia (Ostrom, de Blank, et al., 
2015; Ostrom, Gittleman, et al., 2015) (Fig. 1.1). Furthermore, the overall incidence of brain and 
CNS tumors in children has increased between the years of 2000 and 2010 (Gittleman et al., 
2015), and it is estimated that 4,630 cases will be diagnosed in 2016 (Ostrom, Gittleman, et al., 
2015).  
Despite advances in sequencing technologies and the advent of molecular/cellular-targeted 
therapies in oncology, there is a significant lag in the field of pediatric brain tumors where novel 
targeted therapies are yet to be adopted in the clinic. As a consequence, pediatric brain tumors 
have surpassed leukemias as the leading cause of cancer-related death in children (Patel et al., 
2014; Smith, Altekruse, Adamson, Reaman, & Seibel, 2014). Even comparison with adult brain 
tumors, which are distinct histological and molecular entities from their pediatric counterparts, 
shows that pediatric brain and CNS tumors have a higher incidence and mortality rate than adult 
brain tumors (Fig. 1.2). This necessitates a deeper molecular understanding of pediatric brain 
tumors that can guide development of novel biomarkers and targeted therapies.   
Pediatric brain tumors represent a diverse group of diseases that are classified by the World 
Health Organization (WHO) into large groups based on predominant cell type, location of tumors 
and level of malignancy.  Based on the WHO classification, pediatric brain tumors mainly 
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comprise of glial tumors/gliomas (astrocytomas, oligodendrogliomas, oligoastrocytomas, 
ependymomas), germ cell tumors (GCTs), embryonal tumors of neuronal origin 
(medulloblastoma, atypical teratoid rhabdoid tumors [ATRTs], CNS primitive neuroectodermal 
tumors [PNETs] and epithelial tumors with multiple rosettes [EMTRs]), and other rare tumors 
such as craniopharyngiomas and tumors of mixed neuronal-glial lineages (Louis et al., 2007) 
(Fig. 1.3). Each tumor type has been found to have preference for site of occurrence, with 
majority occurring below a structure called the tentorium cerebeli that divides the forebrain from 
posterior fossa and hindbrain structures. Pediatric tumors are mostly found in infratentorial 
regions such as cerebellum, the optic pathway and the brainstem (Pollack, 1999). Recent large-
scale sequencing studies are helping to add annotation based on mutational context to these 
diverse tumor types, beginning an era of molecular sub-classification, mutation-based diagnosis 
and identification of novel targets. 
Gliomas are the most common primary tumors found in children (52.9%) and are further sub-
divided on the basis of aggressiveness, grade I (benign) to grade IV (most malignant and 
aggressive). Further sub-grouping has resulted in two broad clinical and commonly known 
categories: low-grade gliomas (LGG, grades I and II) and high-grade gliomas (HGG, grades III 
and IV). Amongst these diverse tumor sub-types, we studied the molecular mechanisms driving 
pediatric low-grade gliomas (PLGGs) that are often considered ‘low-risk’ tumors but can lead to 
devastating long-term consequences in children.  
Pediatric Low-Grade Gliomas  
 
PLGGs are the most commonly diagnosed brain tumor in children and represent a heterogeneous 
group of histological entities, ranging from grade I pilocytic astrocytomas (PAs) to grade II 
diffuse astrocytomas (DAs), angiocentric gliomas (AGs), pleomorphic xanthoastrocytomas 
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(PXAs), and gangliogliomas (Louis et al., 2007). These tumors account for 30-50% of the CNS 
tumors in children and are characterized by their slow growth and less aggressive behavior 
(Qaddoumi, Sultan, & Gajjar, 2009). Most PLGG patients have favorable outcomes with surgical 
resection but therapeutic challenges remain in cases with incompletely resected tumors in 
inaccessible brain regions such as the hypothalamus/optic pathway, brain stem and basal ganglia. 
Overall, up to 20% of patients suffer from recurrent, progressive or inoperable disease (Sievert & 
Fisher, 2009).  
Adjuvant radiation and chemotherapy improve progression-free survival, however, these 
regimens are associated with significant long-term morbidities in nearly 65% cases due to toxic 
side effects on the developing CNS (Merchant, Conklin, Wu, Lustig, & Xiong, 2009; Sievert & 
Fisher, 2009; Stokland et al., 2010; Taphoorn et al., 1994). Current chemotherapy regimens used 
in the clinic include carboplatin. vincistrine, vinblastine, cisplatin with etoposide, and  
temozolomide (Ater et al., 2012; Bouffet et al., 2012; Massimino et al., 2010). Survivors often 
suffer from late effects of both disease and treatment such as severe cognitive and neurological 
defects, risk of secondary cancers, neuro-endocrine disorders, infertility and other issues in 
adulthood. Hence, despite a 20-year overall survival of 87% in PLGG patients with current 
treatment options (P. Bandopadhayay et al., 2014), there is a large unmet need for combined 
molecular-histopathological diagnosis of these diverse tumors, and improved treatment plans that 
can target patient-specific mutations leading to better quality of life for survivors.  
Landscape of genomic alterations in PLGGs 
 
More than a decade ago, the first insight into the molecular/genetic alterations of PLGGs came 
from tumors arising due to genetic predisposition syndromes such as neurofibromatosis 1 (NF1) 
associated pilocytic astrocytomas (Gutmann, Donahoe, Brown, James, & Perry, 2000; Kluwe et 
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al., 2001; Lau et al., 2000) and tuberous sclerosis complex (TSC) related LGGs (called 
Subependymal Giant Cell Astrocytoma or SEGA) (Shepherd, Scheithauer, Gomez, Altermatt, & 
Katzmann, 1991). These findings highlighted aberration of canonical signaling pathways driven 
by somatic mutations in NF1 or TSC-associated PLGGs. Subsequently, a plethora of studies 
utilizing cytogenetics, single nucleotide polymorphism (SNP) arrays, Sanger sequencing, next-
generation sequencing (whole-genome, exome and RNA sequencing) and epigenetic mapping 
have helped define the molecular/genetic underpinnings of diverse PLGGs that are not associated 
with genetic predisposition syndromes. These large-scale studies have discovered various 
mutations, gene rearrangements forming gene fusions, and copy number alterations that are 
distinct to specific tumor sub-types.  
As shown in figure 1.4, we have categorized PLGG-associated mutations and gene fusions that 
have been discovered in the past few years by our group and others (D. T. Jones et al., 2009; D. 
T. W. Jones et al., 2013). Such categorization has shown promise in associating the unique 
molecular profiles with clinical progression and therapeutic response in some PLGG sub-types 
(mostly grade I PAs) but further research is required to delineate molecular mechanisms and 
response to therapy for grade II tumors. Furthermore, very few studies have explored the 
therapeutic response of distinct mutations within the same PLGG sub-type (Fig. 1.4) and current 
clinical trials fail to address such detailed molecular classification that could critically determine 
success/failure of PLGG targeted therapies.  
BRAF mutations and gene fusions  
 
Large-scale profiling studies over the past few years have found grade I PAs to have relatively 
stable genomes with limited genetic alterations that often lead to aberrant activation of the 
mitogen associated protein kinase (MAPK) pathway. NF1 associated PLGGs have biallelic 
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inactivation of the NF1 gene resulting in loss of neurofibromin protein. NF1 is known to act as a 
tumor suppressor by inhibiting RAS in the pathway, thereby resulting in aberrant MAPK 
activation in NF1 affected PAs (Gutmann et al., 2000; Kluwe et al., 2001; Lau et al., 2000) (Fig 
1.5). In contrast to NF1 associated tumors that account for 15-20% of PAs, sporadic PAs were 
found to harbor somatic gene rearrangements involving the kinase domain of BRAF gene with a 
gene called KIAA1549, also activating the MAPK pathway (D. T. Jones et al., 2008; Pfister et al., 
2008). BRAF is an upstream kinase involved in the MAPK signaling pathway (Fig 1.5) and the 
KIAA1549-BRAF fusion arises due to tandem duplication at 7q34 followed by fusion of 5’ 
KIAA1549 and 3’ BRAF. The fusion transcript can also activate the PI3K/AKT/mTOR pathway 
via crosstalk between the MAPK and PI3K/mTOR pathways (Kaul, Chen, Emnett, Dahiya, & 
Gutmann, 2012). Almost 65% of sporadic PAs harbor the KIAA1549-BRAF fusion but nearly all 
PAs display constitutive activation of the MAPK pathway via other mutations in the MAPK 
signaling axis (Jacob et al., 2009; D. T. Jones et al., 2008; Sievert et al., 2009) as described 
below. Interestingly, better clinical outcomes are correlated with the occurrence of KIAA1549-
BRAF in cerebellar PAs (Hawkins et al., 2011).  
Next generation sequencing studies have discovered alternative BRAF-activating mutations that 
occur at a lower frequency compared to KIAA1549-BRAF in cerebellar PAs, such as novel BRAF 
gene fusions (FAM131-BRAF, FXFR1-BRAF, MACF1-BRAF, RNF130-BRAF, MKRN130-BRAF, 
GNAI1-BRAF), CRAF/RAF1 gene fusions (QKI-RAF1, SRGAP3-RAF1, FYCO-RAF1) and 
BRAFV600E mutations (Bacon, Endris, & Rappold, 2009; D. T. Jones et al., 2009; D. T. W. 
Jones et al., 2013; J. Zhang et al., 2013) (Fig 1.6). These studies indicate that grade I PAs are 
primarily a single pathway disease where a single hit in the MAPK pathway is sufficient to 
induce neoplasia. Interestingly, studies have shown also that BRAF/other mutation driven MAPK 
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pathway activation can lead to oncogene induced senescence in LGGs (Jacob et al., 2011). This 
partly accounts for their indolent growth pattern and absence of malignant progression to HGGs. 
Non-BRAF mutations and gene fusions 
 
In contrast to the predominance of BRAF alterations in cerebellar PAs, non-cerebellar PAs are 
more commonly associated with FGFR1 and PTPN11 mutations, FGFR1-TACC1 fusions, and 
novel NTRK2 gene fusions (QKI-NTRK2 and NACC2-NTRK2) (Fig 1.6). These tumors occur in 
less surgically accessible brain regions and pose a major therapeutic challenge. Since FGFR and 
NTRK are upstream receptors of the MAPK and PI3K/mTOR pathways, mutations and gene 
fusions can constitutively activate both signaling cascades (D. T. W. Jones et al., 2013).  
Further histopathological annotations have classified another WHO grade I tumor called 
angiocentric glioma (AG) (Buccoliero et al., 2013). These epilepsy-associated, cerebral tumors 
are mostly found in children and young adults and alterations in the MYB gene (truncation of 3’ 
end and MYB-QKI gene fusion) have been found in a few cases of AGs (Ramkissoon et al., 2013; 
J. Zhang et al., 2013). However there is no further information about the mechanism of action and 
specific correlation of MYB alterations with occurrence of AGs. We have addressed these 
questions revolving around MYB-QKI and our findings are described in chapter 3.  
Grade II pediatric gliomas encompass diffuse astrocytomas (DAs), pleomorphic 
xanthoastrocytomas (PXAs) and ganglioglomas. While these tumors are rare in the pediatric 
population, they can lead to significant morbidity in patients due to occurrence at unresectable 
sites in the brain and having diffuse/infiltrative morphology, leading to incomplete surgical 
resection. Furthermore, DAs are found to harbor distinct genetic alterations as compared to 
MAPK altered PAs. These include chromosomal duplication at 8q13.1 leading to truncation of 
negative regulatory domain of the transcription factor MYBL1 (Ramkissoon et al., 2013). 
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Approximately 25% of cerebral gliomas with a diffuse morphology harbor alterations in MYB or 
MYBL1 whereas another 25% show FGFR1 duplication (J. Zhang et al., 2013) (Fig 1.6). FGFR1 
mutated grade II tumors also depict MAPK and PI3K/mTOR alterations. Overall, MYB and 
FGFR mutations are useful biomarkers and effective therapeutic targets for these clinically 
challenging tumors.  
QKI gene fusions: MYB-QKI, QKI-RAF1 and QKI-NTRK2 
In our analysis of whole genome sequencing (WGS), RNA sequencing or exome sequencing data, 
we also found the MAPK pathway to be ubiquitously affected in most PLGGs. Interestingly, we 
found non-BRAF gene fusions mediating changes in these well-known signaling pathways and 
activating other unique oncogenic mechanisms in PLGGs. In particular, we and others have 
identified the recurrence of the gene fusions MYB-QKI, QKI-RAF1 and QKI-NTRK2 that share 
the Quaking (QKI) fusion partner, an RNA binding protein and putative tumor suppressor, fused 
to known proto-oncogenes (D. T. W. Jones et al., 2013; J. Zhang et al., 2013) (Fig 1.7). We refer 
to this new class of gene fusions as Quaking (QKI) fusions and the recurrence of QKI as a fusion 
partner strongly indicates a role for QKI gene fusion mediated oncogenic processes in driving 
PLGGs. This provides a unique platform for identifying the mechanisms by which QKI 
collaborates with distinct fusion partners to drive PLGG pathogenesis, thereby suggesting an 
emergent theme for their contribution to low-grade glioma biology. My thesis will discuss the 
oncogenic mechanism of action and therapeutic targeting of the MYB-QKI and QKI-RAF1 
fusions.  
QKI belongs to a family of RNA binding proteins known as the signal transduction and 
activation of RNA (STAR) proteins. These proteins share a single, highly conserved, maxi K-
homology (KH)–RNA binding domain (RBD). Flanking the KH domain is the N-terminus 
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QUAKING1 (QUA1) domain, required for homodimerization (HD), and the C-terminus 
QUAKING2 (QUA2) domain, necessary for RNA recognition and binding (Vernet & Artzt, 
1997) (Fig 1.7). QKI isoforms (QKI 5/6/7) act at various levels of post-transcriptional gene 
regulation, including mRNA export, RNA stability, pre-mRNA splicing and protein translation, 
in several cell-specific contexts. The most well studied role of QKI has been its regulation of glial 
development and myelination in the CNS (Vernet & Artzt, 1997). Interestingly, alterations in 
QKI expression are found in ~ 30% of HGGs (A. J. Chen et al., 2012) where QKI acts as a 
putative tumor suppressor gene. Furthermore, recent large-scale genomic analyses have revealed 
QKI as a critical cancer gene lost in several cancer types (Lawrence et al., 2014). However, 
structural alterations of QKI seen in the MYB-QKI, QKI-RAF1 and QKI-NTRK2 gene fusions 
have not been previously described. My structural analysis of QKI-RAF1 and QKI-NTRK2 
reveals that rearrangement of chromosome 6q results in a loss of QKI’s C-terminal Y-rich region 
in addition to loss of the QUA2 domain in QKI-RAF, whereas MYB-QKI loses QKI N-terminal 
regions, including RBD and HD domains (Fig 1.7). However, QKI retains the QUA1 region in 
QKI-NTRK2 and QKI-RAF1 fusion proteins that has homo-dimerization properties.  
MYB was first discovered as the cellular homolog (c-myb) of highly oncogenic v-myb found in 
the chicken leukemia viruses AMV and E26 (Gonda & Bishop, 1983; Klempnauer, Gonda, & 
Bishop, 1982). This association between altered MYB and avian leukemias suggested a potential 
role for MYB as a proto-oncogene in human cancer. During normal development, MYB functions 
as a transcription factor that regulates proliferation and differentiation in specific cell lineages. In 
hematopoiesis, MYB plays a critical role in maintaining the undifferentiated state of 
hematopoietic stem cells (Sicurella et al., 2001). However, MYB expression declines postnatally 
in most differentiated tissues including the CNS, with some expression persisting in the 
neurogenic foci in adult brain (Malaterre et al., 2008). This implicates that MYB plays a role in 
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stimulating proliferation and suppressing differentiation. These functions are consistent with 
MYB’s established role as a proto-oncogene in tumors. However, the mechanism of MYB 
dysregulation differs in different cancer types. In human leukemias and several epithelial cancers, 
MYB is often deregulated via chromosomal translocations, activating truncations, and/or 
amplifications (Pelicci, Lanfrancone, Brathwaite, Wolman, & Dalla-Favera, 1984; Zhou & Ness, 
2011). Provided that the N-terminus of MYB contains the DNA binding domain (DBD) and the 
C-terminus contains a negative regulatory domain (NRD) (Fig 1.7), which interacts with the 
DBD to auto-inhibit its function, alterations in the N or C terminus both enhance the 
transformative capacity of MYB. This has been evidenced by the up-regulation of MYB activity 
in cancers with C-terminally truncated MYB (Dash, Orrico, & Ness, 1996; Zhou & Ness, 2011). 
In addition, loss of the 3’UTR of MYB, that harbors negative regulatory microRNA binding sites, 
has also been found in several cancers (Fehr et al., 2011; M. Persson et al., 2009). Interestingly, 
the MYB-QKI fusion leads to loss of MYB NRD (Fig 1.7) that could lead to constitutive 
activation of MYB in MYB-QKI. This observation, along with loss of QKI RBD, forms the basis 
of my hypothesis for Aim 1 of my thesis (chapter 2), as described below.  
AIM 1: Investigate the oncogenic mechanism of action of MYB-QKI in PLGGs with a focus on 
independent and collaborative roles of MYB and QKI in mediating gliomagenesis. This aim will 
test the hypothesis that there is a gain-of-function of the MYB proto-oncogene via loss of its 
regulatory elements along with loss of tumor suppressor functions of QKI in a specific subset 
of PLGGs called angiocentric gliomas. 
RAF-1 (or CRAF) is a serine-threonine kinase involved in the MAPK signaling cascade and is 
one of the three existing RAF isoforms (A-RAF, B-RAF, C-RAF). All three RAF proteins share 
similar protein domains, common mechanisms of activation and downstream effectors. Activation 
of up-stream RAS by tyrosine kinase auto-phosphorylation recruits RAF to the membrane where 
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RAF is activated and in turn activates the MAPK/ERK pathway by phosphorylating the 
MAPK/ERK kinase (MEK) (Emerson et al., 1995; Moodie, Willumsen, Weber, & Wolfman, 
1993; Nassar et al., 1995). The N-terminal domains of RAF1 physically inhibit the kinase activity 
of RAF1 (Cutler, Stephens, Saracino, & Morrison, 1998) and membrane recruitment by RAS 
relieves this negative regulation of RAF kinase activity (Fig. 1.5). The structural gene 
rearrangement in QKI-RAF1 leads to loss of N-terminal auto-inhibitory domains, thereby 
suggesting constitutive kinase activity. This observation, along with loss of portion of QKI RBD, 
forms the basis of my hypothesis for Aim 2 (chapter 3), of my thesis, as described below. 
AIM 2: Investigate the oncogenic mechanism of action of QKI-RAF1 in PLGGs with a focus on 
independent and collaborative roles of QKI and RAF1 in mediating gliomagenesis. This aim will 
test the hypothesis that dimerization domains in truncated QKI contribute to constitutive 
homo/hetero-dimerization of QKI-RAF1, thereby causing activation of downstream MAPK and 
PI3K pathway and oncogenic transformation.  
These aims would explore an unaddressed avenue in the field of oncogenic gene fusions where 
usually one fusion partner is found to drive transformation. Our study will expose unique 
collaborative mechanisms between fusion partners that lead to pediatric brain tumors and could 
also provide mechanistic insight into the oncogenic mechanism mediated by gene fusions in adult 
cancers.  
Targeted therapy for PLGGs: Need for molecular-based diagnosis and 
patient stratification for personalized medicine 
Due to the tight association of specific mutations/gene fusions with PLGG tumor subtypes, 
PLGGs are an excellent candidate for molecular diagnosis and targeted therapy. Some efforts 
towards this end and future possibilities are described below. 
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MAPK/PI3K/mTOR targeted inhibitors 
Due to extensive involvement of the RAF proteins and subsequent MAPK/PI3K pathway 
activation in multiple cancers, several RAF and MAPK-targeted small molecule inhibitors have 
been developed in the past few years. Pharmacological intervention with RAF (vemurafenib and 
dabrafenib) and MEK (trametinib) inhibitors has significantly improved median survival of 
melanoma patients with BRAF alterations (Long et al., 2011). Despite its success against the 
constitutively active BRAF V600E mutation found in melanomas, when tested in PLGGs 
containing BRAF fusions (KIAA1549-BRAF) or MAPK pathway activation mutations other than 
BRAFV600E, vemurafenib induced paradoxical activation (A. J. Sievert et al., 2013). This is due 
to stabilization of RAS-dependent RAF dimerization by RAF inhibitors (vemurafenib or its 
research analog PLX4720) in cells expressing wild-type RAF proteins (Cutler et al., 1998; 
Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2011). Even a phase II study 
with sorafenib (multi-kinase inhibitor towards BRAF) for MAPK-altered PLGGs showed 
significant early tumor progression due to paradoxical activation of the MAPK pathway 
(Karajannis et al., 2014). These findings highlight the therapeutic nuances of targeting PLGGs 
and how important it is to understand the distinct molecular mechanisms driving distinct tumor 
types, making universal therapy unattainable.    
We have previously also shown that the KIAA1549-BRAF fusions act as dimers and lead to 
paradoxical activation of MAPK pathway with first generation RAF inhibitors, but are inhibited 
by paradox breaker RAF inhibitors such as PLX8394 (A. J. Sievert et al., 2013). Recently, pan-
RAF dimer inhibitors LY3009120 and BGB-283 have shown to be efficacious in RAF mutant 
tumors (Henry et al., 2015; Peng et al., 2015; Tang et al., 2015) but how these drugs will impact 
RAF fusions in PLGGs, is yet to be known. In addition to targeting upstream in the MAPK and 
PI3K pathway, downstream inhibitors are also being evaluated in clinical trials. Phase I/II studies 
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using the MEK1/2 inhibitor Selumetinib (AZD6244) for children with refractory/recurrent low-
grade gliomas is currently underway (ClinicalTrials.gov Identifier: NCT01089101 and 
NCT01386450). Another phase II study is evaluating efficacy of single-agent Everolimus (or 
RAD001, an mTOR2 inhibitor) for progressive pediatric low-grade gliomas (ClinicalTrials.gov 
Identifier: NCT01734512). These studies are the first to test targeted inhibitors on children with 
PLGGs and assess benefit over standard therapies. However, given the diversity in molecular 
aberrations, such clinical studies need to be combined with comprehensive mutation screening to 
ensure that PLGG patients are receiving personalized and effective therapy.  
Novel therapeutic avenues: Epigenetic modulators 
Epigenetic modifications are genomic changes that do not directly alter the DNA sequence, 
including different mechanisms to affect the chemical properties of DNA or DNA packaging 
proteins (histones). Oncogenic alterations in epigenetic modulators have been described for 
several adult and pediatric tumors and are expanding the therapeutic and diagnostic toolkit for 
human cancers.  
Pediatric HGGs (Grade IV glioblastoma) display a range of somatic mutations in the histone 3 
(H3) variant H3.3 encoded by the H3F3A gene, such as the K27M and G34R/V mutations 
(Schwartzentruber et al., 2012; G. Wu et al., 2012). K27M mutations in H3.3 and another histone 
variant H3.1 (HIST1H3B) are found in a large proportion of DIPGs, another devastating PHGG 
with a dismal 5-year survival of less than 1% (Khuong-Quang et al., 2012; G. Wu et al., 2012). 
Recent studies have demonstrated, for the first time, some efficacy of epigenetic therapy in 
DIPGs. The multi-histone deacetylase (HDAC) inhibitor panobinostat showed surprising efficacy 
in suppressing in vitro and in vivo DIPG mice xenograft growth (Grasso et al., 2015). Single-
agent therapy with the histone demethylase inhibitor GSK-J4 can suppress DIPG cell lines 
(Hashizume et al., 2014) but combination with panobinostat has shown synergistic inhibition of 
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DIPG patient-derived lines (Grasso et al., 2015). Such epigenetic modifying therapies are opening 
the preclinical realm for PHGGs where no targeted therapies exist.  
PLGGs have been found to harbor H3F3A mutations in very rare cases of DAs and PAs (D. T. W. 
Jones et al., 2013) with no other predominant epigenetic mutations. Furthermore, a group very 
recently found pilocytic astrocytomas (PAs) to have distinct methylation signatures with 
hypomethylation at multiple CpG sites, thereby suggesting uncontrolled gene transcription 
(Jeyapalan et al., 2016). These findings suggest epigenetic modifications to precede gene 
mutation/chromosomal rearrangement events that could then drive aberrant expression of PLGG-
specific oncogenes. As such, epigenetic targeting could hold some promise for PLGGs but this 
needs to be explored further. Our findings in aim 1 (chapter 2) with MYB-QKI will provide some 
mechanistic insight into how epigenetic modification can mediate PLGGs. 
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Tables and Figures 
Figure 1.1 
      
Figure 1.1. Comparison of incidence rates of various childhood cancers by age. Plots 
showing average annual age-related incidence of all primary brain and CNS tumors in 
comparison to other cancers (leukemias, lymphomas and other solid tumors) in children. (a) 
Infants (<1 Year Old), (b) Children 1–4 Years, (c) Children 5–9 Years, and (d) Children 10–14 
Years (source CBTRUS 2007–2011, USCS 2007–2011)(Ostrom, de Blank, et al., 2015). Figure 
adapted from Quinn T. Ostrom et al. Neuro Oncol 2015. 
 
  
 
 
<1 year old 1-4 years old 
5-9 years old 10-14 years old 
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Figure 1.2 
 
Figure 1.2. Comparison of incidence rates and mortality rates between adult and 
childhood cancers. Plots showing average annual age-related incidence of all primary brain and 
CNS tumors in comparison to other cancers in (a) adults (+20 years old) and (b) children and 
adolescents (0-19 years old) and mortality rates of all primary brain and CNS tumors as 
compared to other common cancers in c) adults (age 20+ years) and d) children and adolescents 
(age 0-19 years), CBTRUS statistical report: npcr and seer 2008-2012,USCS2008-2011b,NCVS 
2008-2012 (Ostrom, de Blank, et al., 2015). Figure adapted from Quinn t. Qstrom et al. Neuro 
oncol 2015. 
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Figure 1.3 
 
 
 
Figure 1.3. Classification of pediatric brain tumors by histology. Pie chart showing 
distribution of all primary brain and CNS tumors by histology groupings in patients 0–14 Years, 
N = 16,044 (CBTRUS 2007–2011) (Ostrom, de Blank, et al., 2015). Figure adapted from Quinn 
T. Ostrom et al. Neuro Oncol 2015. 
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Figure 1.4 
 
 
Figure 1.4. Grade I and Grade II PLGGs classified on the basis of genetic/molecular 
alterations. Mutations grouped into BRAF, FGFR, CRAF/RAF1, NTRK and MYB families 
based on known oncogenes involved. Family of mutations can be further grouped within grade I 
and grade II astrocytomas as low-grade tumor sub-types have distinct molecular signatures. AG- 
angiocentric glioma, PXA- pleomorphic xanthoastrocytoma, GG- ganglioglioma.  
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Figure 1.5 
 
 
Figure 1.5. Simplified linear representation of the RAS/RAF/MEK/ERK (MAPK) 
pathway. Upon receiving upstream signal from a growth factor activated receptor kinase, the 
RAS protein is activated and leads to further stimulates downstream RAF kinases. NF1 serves to 
negatively regulate RAS by preventing RAS activation leading to inhibition of the MAPK/ERK 
pathway. Activated RAS proteins recruit RAF kinases to the membrane that leads to their 
dimerization and consequent activation. RAF kinases then phosphorylate downstream MEK1/2 
kinases, which then can phosphorylate ERK. The MAPK pathway eventually leads to 
transcriptional changes in the nucleus that leads to cell proliferation and growth.    
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Figure 1.6 
 
 
Figure 1.6. Breakpoints in BRAF forming in-frame gene fusions in PLGGs. Linear 
structure of BRAF gene on chromosome 7q34 showing breakpoints at exon 9 (KIAA1549-BRAF, 
FAM131B-BRAF, MACF1-BRAF and RNF130-BRAF), exon 10 (KIAA1549-BRAF, FXR1-BRAF 
and GNAI-BRAF) and exon 11 (KIAA1549-BRAF, CLC6-BRAF and MKRN1-BRAF) to form the 
respective oncogenic gene fusions in PLGG patients. The conserved region 3 is retained in all 
BRAF fusions (shown in green). BRAF point mutations (R506VLRK507, R509H and V600E) are 
depicted in the ATP binding domain and activation segment of the kinase.  
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Figure 1.7 
 
 
Figure 1.7. Functional protein domains of (A) wild type QKI, MYB, RAF1 and NTRK2 
proteins, (B) QKI fusions found in PLGG patient samples, MYB-QKI5/6, QKI-RAF1 and QKI-
NTRK2 and the retained protein domains in truncated QKI and truncated MYB/ RAF1/ NTRK2. 
DBD- DNA binding domain, TAD-trans-activation domain, NRD-negative-regulatory domain, 
TM-transmembrane domain. 
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The data in the following chapter are published in Nature Genetics 2016 Mar; 48(3):273-82. 
doi: 10.1038/ng.3500. The Nature Publishing Group allows for authors to own copyright to their 
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CHAPTER 2: MYB-QKI rearrangements in angiocentric gliomas drive 
oncogenicity through a tripartite mechanism 
 
Summary 
Angiocentric gliomas are pediatric low-grade gliomas (PLGGs) without known recurrent genetic 
drivers. We performed genomic analysis of new and published data from 249 PLGGs including 
19 Angiocentric Gliomas. We identified MYB-QKI fusions as a specific and single candidate 
driver event in Angiocentric Gliomas. In vitro and in vivo functional studies show MYB-QKI 
rearrangements promote tumorigenesis through three mechanisms: MYB activation by truncation, 
enhancer translocation driving aberrant MYB-QKI expression, and hemizygous loss of the tumor 
suppressor QKI. This represents the first example of a single driver rearrangement simultaneously 
transforming cells via three genetic and epigenetic mechanisms in a tumor. 
Introduction 
Pediatric low-grade gliomas (PLGG) encompass a heterogeneous group of World Health 
Organization grade I and II tumors that collectively represent the most common pediatric brain 
tumor. PLGGs undergo frequent alterations in the MAPK pathway and in MYB family genes, 
including MYBL1 and MYB (Ramkissoon et al., 2013; J. Zhang et al., 2013). Alterations in MYB 
are heterogeneous; several fusion partners have been reported as rare events in PLGGs 
(Ramkissoon et al., 2013). The frequency of specific alterations and associations with histological 
subtypes are unknown.  
Angiocentric Gliomas arise in the temporal lobe and share histologic features with astrocytomas 
and ependymomas (Lellouch-Tubiana et al., 2005; M. Wang et al., 2005). We previously 
identified one Angiocentric Glioma with deletion of the 3’ region of MYB (Ramkissoon et al., 
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2013) and one other Angiocentric Glioma has been reported to harbor a MYB-QKI rearrangement 
(J. Zhang et al., 2013). However, the nature and incidence of MYB alterations in Angiocentric 
Glioma has not been determined. Furthermore, oncogenicity of MYB family transcription factors 
in the CNS and the mechanisms by which they contribute to gliomagenesis are yet to be defined.   
To address these questions, we performed a combined analysis of newly generated and published 
PLGG genomic datasets (D. T. W. Jones et al., 2013; Ramkissoon et al., 2013; J. Zhang et al., 
2013). We found MYB-QKI rearrangements to be the most common event involving a MYB 
family member and to be specific to Angiocentric Gliomas. We also found that this 
rearrangement contributes to oncogenicity through three mechanisms: generation of oncogenic 
MYB-QKI, enhancer translocation that establishes an auto-regulatory feedback loop selectively 
driving MYB-QKI expression, and partial loss of expression of QKI, a tumor suppressor gene. 
Results 
Angiocentric Gliomas exhibit recurrent MYB-QKI rearrangements 
Previously published genomic analyses of PLGGs did not individually contain sufficient numbers 
of rare histologic subtypes for statistical power to detect recurrent aberrations. To address this we 
performed a combined genomic analysis of whole-genome sequencing (WGS) and/or RNA-
sequencing (RNA-seq) data from 172 PLGGs spanning ten histologic subtypes (Table 2.1), 
including 145 published samples (D. T. W. Jones et al., 2013; J. Zhang et al., 2013) and 27 rare 
PLGGs that are new to this study. We performed analyses of significantly recurrent somatic 
genetic events across all samples with WGS or RNA-seq data (Fig. 2.1 and Tables 2.2 and 2.3). 
We observed recurrent somatic alterations in 154 tumors (90%), including all 140 tumors subject 
to WGS. Rearrangements or structural alterations were observed in 129 tumors (83%; Fig. 2.2a, 
Table 2.1).   
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Rearrangements involving MYB family members (MYB, MYBL1) were the second-most recurrent 
alteration, affecting 16 tumors (10%), predominantly Diffuse Astrocytomas and Angiocentric 
Gliomas (Fig. 2.1 and 2.2a). Six of seven Angiocentric Gliomas, including all tumors subject to 
central pathology review, exhibited intra-chromosomal deletions resulting in MYB-QKI 
rearrangements. The other Angiocentric Glioma, which was not centrally reviewed, contained a 
MYB-ESR1 rearrangement.  
Although MYB rearrangements have been described in PLGGs (Ramkissoon et al., 2013; J. Zhang 
et al., 2013), we were struck by two novel findings: QKI was the most frequent fusion partner, 
and MYB-QKI fusions were near-universal in Angiocentric Gliomas. For validation we identified 
studied 12 additional Angiocentric Gliomas with only FFPE tissue using targeted assays. Nine 
Angiocentric Gliomas were analyzed by FISH to detect MYB rearrangement or deletion (Fig.2. 
2b), and three Angiocentric Gliomas were analyzed by WES and/or aCGH (Fig. 2.3). All 12 
harbored MYB aberrations.  
In total, all 19 Angiocentric Gliomas profiled by WGS, RNA-seq, WES, FISH, or aCGH 
displayed MYB alterations, and in six of the seven cases in which its fusion partner could be 
detected, MYB was fused to QKI. In tumors confirmed to harbor MYB-QKI, the genetic event 
appeared to be present in the majority of cells, although evidence of heterogeneity (aberration in 
~50% of tumor cells) was observed by FISH in 2/5 tumors with sufficient cells for quantitative 
scoring. 
 MYB-QKI rearrangements appeared specific to Angiocentric Glioma. None of the 147 non-
Angiocentric Gliomas profiled with WGS or RNA-seq exhibited MYB-QKI fusions (p<0.0001, 
Fig. 2.2c). We also evaluated MYB alterations in an additional 65 PLGGs from two separate 
cohorts: 10 non-Angiocentric Gliomas analyzed by FISH and 55 non-Angiocentric Gliomas 
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evaluated by whole-exome sequencing (WES) and/or array CGH.  Only one of these tumors 
exhibited alterations of MYB (vs 19/19 Angiocentric Gliomas; p<0.0001) (Fig. 2.3 and Table 
2.1). This tumor was designated not-otherwise-specified on research review but had been 
diagnosed as Angiocentric Glioma at the referring institution. Five tumors evaluated by WES or 
aCGH exhibited alterations of MYBL1; these were all Diffuse Astrocytomas. The FISH assays, 
aCGH, and WES, though able to detect MYB alterations, were unable to characterize its fusion 
partners.  
All MYB-QKI rearrangements had breakpoints within intron 4 of QKI while the MYB breakpoint 
varied from intron 9 to 15; all were predicted to express an in-frame fusion protein MYB-QKI 
(Fig. 2.2d). We identified fusion mRNA transcripts by RNA-seq (Fig. 2d) and observed copy-
number breakpoints in these genes from WGS data (Fig. 2.2e). 
In the WGS/RNA-seq cohort we also observed rearrangements involving QKI but not MYB in 
three supratentorial Pilocytic Astrocytomas (PAs), and rearrangements involving MYB or MYBL1 
but not QKI in nine tumors, seven of which were Diffuse Astrocytomas. Across the entire cohort 
of 172 tumors profiled with WGS and/or RNA-seq, 10% harbored alterations of either MYB 
family members or QKI.  
MYB and QKI have contrasting roles in cortical brain 
MYB proteins are transcription factors characterized by highly conserved DNA-binding motifs. 
First identified as v-myb (Klempnauer, Bonifer, & Sippel, 1986; Klempnauer et al., 1982; Ness, 
Marknell, & Graf, 1989) the cellular proto-oncogene counterpart c-MYB is comprised of a N-
terminus that contains helix-turn-helix (HTH) DNA binding motifs followed by a transcriptional 
activation domain and a C-terminal negative regulatory domain (Sakura et al., 1989). Full-length 
MYB is non-transforming or only weakly transforming in vitro (Gonda, Buckmaster, & Ramsay, 
26 
 
1989), but C-terminal MYB truncations are oncogenic (Gonda et al., 1989; Grässer, Graf, & 
Lipsick, 1991; Y. L. Hu, Ramsay, Kanei-Ishii, Ishii, & Gonda, 1991; Press, Reddy, & Ewert, 
1994). MYB-QKI breakpoints in MYB intron 9 to 15 are predicted to result in C-terminal 
truncation of MYB. 
MYB is not expressed in the postnatal brain cortex, where Angiocentric Gliomas occur. We 
examined RNA-seq data of normal tissues (G. Consortium, 2013) and found MYB expression to 
be negligible in human brain cortex and substantially lower than MYB expression in colon, breast, 
blood, esophagus, or skin (Fig. 2.4a). Likewise, immunohistochemistry of adult human frontal 
cortex and white matter were negative for MYB (Fig. 2.4b and 2.4c); however we detected high 
MYB expression in human fetal neural progenitor cells generated from the ganglionic eminence 
at 22 weeks gestation (Fig. 2.4d and 2.4e). 
In mice MYB is expressed in E14.5 neural progenitor cells of the ganglionic eminence sub-
ventricular region (Fig. 2.4f-i). In adult mice we detected expression in the ependyma/sub-
ventricular zone (Fig. 2.4j-k), consistent with previous reports of MYB expression in mouse 
progenitor cells but not in cortical brain (Malaterre et al., 2008). 
QKI encodes the STAR (Signal transduction and activation of RNA) RNA-binding protein 
Quaking, which plays an essential role in oligodendroglial differentiation (Friedrich, 1974) and is 
widely expressed in the nervous system. Deletions of QKI have been suggested to be oncogenic 
in a number of cancers including glioblastoma (Yin et al., 2009), prostate cancer (Y. Zhao et al., 
2014), and gastric cancer (Bian et al., 2012). In copy-number analyses of 10,570 cancers within 
the Cancer Genome Atlas (Zack et al., 2013), QKI was one of two genes in a deletion peak in 
adult glioblastomas (Fig. 2.4l), renal clear cell, and cervical squamous cell carcinomas. It was 
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also in larger peak regions of significant deletion in low-grade gliomas and bladder and 
adrenocortical carcinomas. Focal QKI deletions were observed in over 10% of glioblastomas. 
The MYB-QKI fusion protein is expected to retain the MYB N-terminal HTH DNA binding 
motifs fused to the QKI C-terminus (Fig. 2.4m). The QKI N-terminal KH RNA-binding motif is 
lost, while C-terminal alternative splice sites are preserved. The splice variant MYB-QKI5 retains 
a nuclear localizing motif which is not present in the splice variant MYB-QKI6 (J. Wu, Zhou, 
Tonissen, Tee, & Artzt, 1999). Fusions that contain only exons 1-9 of MYB also lose the MYB 
negative regulatory domain (designated short variant). 
The findings that both MYB and QKI are disrupted suggest that MYB-QKI rearrangements may be 
oncogenic through the additive effects of alterations in both MYB and QKI. The lack of 
expression of MYB in normal post-natal human cortical brain regions also suggests that the 
rearrangement drives aberrant expression of the fusion allele. We therefore characterized 
mechanisms through which MYB-QKI rearrangements may contribute to aberrant MYB-QKI 
expression and evaluated the oncogenic potential of both genes. 
MYB-QKI functions as a transcription factor 
We performed genome-wide gene expression analyses of three independently-generated pools of 
mouse neural stem cells (mNSCs) engineered to stably over-express MYB-QKI5, MYB-QKI6, 
truncated MYB including exons 1-9 (MYBtrExon1-9), or eGFP. Relative to eGFP-expressing cells, 
those expressing MYB-QKI5 and MYB-QKI6 exhibited significantly different expression of 
1621 and 1947 genes, respectively, with 1029 genes overlapping (p<0.0001; Table 2.4). Gene-set 
enrichment analysis revealed expression of either MYBtrExon1-9 or MYB-QKI was associated with 
enrichment of signatures of MYB pathway activation (p<0.0001, Table 2.5). 
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We defined a MYB-QKI gene expression signature comprising the 50 genes whose differential 
expression correlated most with its expression (Fig. 2.5a). These genes include KIT and CDK6, 
previously reported to be associated with MYB activation (Gao et al., 2014). 
We performed chromatin immunoprecipitation with parallel sequencing (ChIP-seq) in mNSCs 
expressing MYB-QKI, using an antibody which recognizes the N’ terminus of MYB and another 
antibody against H3K27ac, which defines the location of enhancer regions.  We found MYB-
QKI5 bound 3,672 sites across the genome (92% of these sites contain a MYB binding motif) and 
H3K27ac bound 9,122 sites, with overlap at 1,907 sites (52% of MYB binding sites, p<0.0001) 
(Fig. 2.5b). These findings are consistent with reports in T-cell ALL, where MYB binding was 
highly correlated with H3K27ac defined enhancers (Mansour et al., 2014). We also identified 
MYB-QKI binding to the endogenous Myb promoter (Fig. 2.6a). 
MYB-QKI5 binding sites were located within 100kb of 88% (22/25) of upregulated genes in the 
MYB-QKI signature but only 40% (10/25) of downregulated genes (p<0.001; Fig. 2.5c). Each of 
the MYB-QKI binding sites associated with an upregulated gene was associated with an 
H3K27ac enhancer peak, while only 70% of MYB-QKI binding sites at downregulated genes 
overlapped enhancers (p=0.003). 
The MYB-QKI fusion protein can activate transcription through binding of MYB consensus 
binding motifs. We generated a luciferase-reporter construct using known MYB binding sites 
from the target promoter mim-1 (Ness et al., 1989), and co-transfected this reporter with 
MYBtrExon1-9, MYB-QKI, or full-length MYB, in 293T cells. We observed a slight induction of 
mim-1 promoter activity with transfection with full length MYB compared to the control vector. 
The greatest induction of mim-1 promoter activity was observed upon co-transfection with 
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MYBtrExon1-9 or MYB-QKI (Fig. 2.5d and 2.6b), with MYBtrExon1-9 having the highest level of 
activity.   
Angiocentric Gliomas exhibited significantly higher expression of the MYB-QKI signature 
relative to normal pediatric brain (p=0.001) and PLGGs without MYB-QKI alterations 
(p=0.0011) (Fig. 2.5e). PLGGs exhibited increased expression of genes associated with MYB 
pathway activation compared to normal brain (p=0.0003), but this was not specific to MYB-QKI 
rearranged tumors, and was of lower magnitude than the difference observed with the MYB-QKI 
signature (Fig. 2.6c).  
MYB-QKI rearrangements drive aberrant expression of truncated MYB 
Angiocentric Gliomas with MYB-QKI exhibit significantly higher MYB expression relative to 
normal pediatric cortical brain (p=0.0062) or to PLGGs with BRAF or FGFR alterations (p=0.03) 
(Fig. 2.7a). The MYB that is expressed is truncated and corresponds to the exons retained in the 
rearranged MYB-QKI allele. Three Angiocentric Gliomas harbored MYB-QKI rearrangement 
breakpoints between exons 9 and 10 of MYB. These exhibit increased expression of MYB exons 
1-9 relative to PLGGs that do not harbor MYB-QKI (p<0.05), but minimal expression of the 
remaining exons (Fig. 2.7b). These data support the selective, aberrant regulation of expression 
of truncated MYB via MYB-QKI. 
The MYB-QKI rearrangement results in enhancer translocation 
Aberrant oncogene expression can result from enhancer translocation (Northcott et al., 2014). In 
published H3K27ac enhancer profiles from normal human cortical brain samples (E. P. 
Consortium, 2012), MYB is not associated with H3K27ac enhancer peaks, consistent with the 
finding that MYB is not expressed. In contrast, QKI, which is expressed, is associated with several 
H3K27ac peaks, including sequences at the 3’ end of QKI (Fig. 2.7c, d, e). The MYB-QKI 
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rearrangement is predicted to bring these 3’ QKI-associated H3K27ac enhancer elements to 
within only 15kb of the MYB promoter (Fig. 2.7e).  
H3K27ac enhancer profiling of two human Angiocentric Gliomas expressing MYB-QKI 
confirmed the presence of active enhancer elements that are translocated proximally towards the 
MYB promoter (Figs. 2.8a and 2.9). ChIP-seq revealed multiple H3K27ac peaks associated with 
3’ QKI, similar to the peaks observed in normal human brain, and in a BRAF-duplicated 
supratentorial pilocytic astrocytoma. We also observed enhancers within 10kb of 3’ QKI and a 
larger cluster of super-enhancers 100-500kb 3’ to QKI (Q3SE1 and Q3SE2). In Angiocentric 
Gliomas with MYB-QKI, these enhancers are translocated proximally towards the MYB promoter.  
We observed an aberrant enhancer associated with the MYB promoter in MYB-QKI defined 
Angiocentric Glioma (Fig. 2.8a). Normal human cortical brain is not associated with H3K27ac 
MYB-related enhancers, and indeed we did not observe formation of H3K27ac MYB enhancer 
peaks in the Pilocytic Astrocytoma (Fig. 2.10). However, in both Angiocentric Gliomas, we 
observed a large H3K27ac peak associated with the MYB promoter (M5E1). RNA-seq revealed 
expression of the first nine exons of MYB corresponding to those retained in the rearrangement, 
suggesting that the aberrant M5E1 enhancer is regulating expression of truncated MYB from the 
rearranged allele. The lack of full-length MYB expression indicates the aberrant enhancer does not 
regulate the remaining wild-type MYB allele. 
We examined whether MYB-QKI was able to functionally activate the MYB promoter by creating 
a luciferase-reporter construct possessing the human MYB-promoter (MYB-luc). We observed 
significant induction of MYB promoter activity in U87 cells stably expressing MYB-QKI with 
MYB-luc as compared to U87 cells containing MYB-luc or the promoter-less control luciferase 
construct alone (Fig. 2.8c). This suggests MYB-QKI contributes to an auto-regulatory feedback 
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loop, possibly by binding to the MYB promoter. MYB-QKI activated the MYB promoter in two 
additional cellular contexts (HEK 293T and NIH-3T3 cells, Fig. 2.11). 
We predicted that enhancers in the QKI 3’ UTR could aberrantly activate the MYB promoter 
when translocated, thereby further driving MYB-QKI expression. We cloned the proximal QKI 
3’UTR enhancer sequence (Q3E1) upstream of the human MYB promoter in the MYB-luc 
construct. Baseline activity of the Q3E1-MYB-luc promoter construct was higher than with MYB-
luc alone in U87 glioma cells (Fig. 2.8c), increasing activation by approximately 1.5 fold, a level 
of activation shown to harbor biological relevance in other diseases (Menzel et al., 2007). 
Expression of MYB-QKI with Q3E1-MYB-luc led to even higher activity, again consistent with 
an auto-regulatory feedback loop in the presence of the fusion protein (Fig. 2.8c).  
The MYB-QKI fusion protein is oncogenic 
Expression of truncated MYB has previously been reported to be oncogenic (Gonda et al., 1989; 
Y. L. Hu et al., 1991; Press et al., 1994). In mNSCs, overexpression of MYB exons 1-9 (short 
variant) increased cell proliferation rates compared to eGFP controls (Figs. 2.12a and 2.11b), 
while in NIH-3T3 cells overexpression of MYBtr (exons 1-15), but not full-length MYB, induced 
tumors when injected into mouse flanks (Figs. 2.12b and 2.11b).  Furthermore mNSCs 
expressing MYBtr induced diffuse gliomas on average 100 days post intracranial injection 
(Figure 6e, f). These tumors expressed OLIG2 and GFAP in a subset of tumor cells, a pattern 
similar to that observed in human diffuse gliomas (Fig. 2.11c).   
To test whether MYB-QKI fusions are oncogenic, we stably expressed MYB-QKI5 and MYB-
QKI6 in mNSCs and NIH3T3 cells. In mNSCs, overexpression of either isoform led to 
significantly increased proliferation compared to eGFP (Figs. 2.12c and 2.11b), p<0.0001.  
Similarly both isoforms induced anchorage-independent growth in NIH-3T3 cells (Fig. 2.13a); in 
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vivo, overexpression of both MYB-QKI5 and MYB-QKI6, but not full-length MYB, led to tumor 
formation as flank xenografts (Fig. 2.12b).  Intracranial injections of mNSCs overexpressing 
MYB-QKI5 or MYB-QKI6 formed gliomas with infiltrating tumor cells with some evidence of 
enhanced growth around vessels and a clustered growth pattern, features similar to Angiocentric 
Glioma and distinct from the histology seen adult glioblastoma models (e.g. 
Ink4a/ARF:EGFRvIII) (Bachoo et al., 2002). However these tumors differed from human 
Angiocentric Gliomas in that they had high-grade features with frequent mitoses and marked 
cytologic atypia (Fig. 2.12e). Immunohistochemical analysis showed diffuse GFAP expression 
and a subset of OLIG2 positive tumor cells, a pattern similar to that seen in human Angiocentric 
Gliomas (Fig. 2.11c).   
In total, we established flank injections in 15 mice with NIH-3T3 cells over-expressing either 
MYBtr or MYB-QKI (and five vector controls), and 29 intracranial injections of mNSC 
expressing MYBtr or MYB-QKI (15 vector controls) (Fig. 2.13b). We observed flank tumors in 
all 15 mice injected with NIH-3T3 cells over-expressing either MYBtr or MYB-QKI and five 
intracranial tumors from mice injected with mNSCs expressing MYBtr or MYB-QKI.  We did 
not observe tumors in any vector controls. These data represent a significant enrichment of tumor 
formation in cells expressing MYBtr or MYB-QKI (p<0.0001). 
The MYB-QKI rearrangement disrupts QKI, a tumor suppressor 
We were interested in understanding how disruption of QKI may contribute to oncogenicity in 
tumors that harbor MYB-QKI. Exon-specific RNA-seq analysis of Angiocentric Gliomas with 
MYB-QKI (n=4) showed reduced expression of QKI compared to PLGGs that harbor BRAF 
alterations (n=5) (Fig. 2.14a). These data suggest that the MYB-QKI rearrangement may 
contribute to tumor formation through reduced expression of QKI, a tumor suppressor gene.  
33 
 
Indeed, suppressing wild-type Qk using shRNAs that target the first four exons of Qk led to 
increased proliferation of mNSCs, with the greatest increase observed in the context of pre-
existing MYB-QKI expression. In mNSCs over-expressing MYBtr, MYB-QKI5 or MYB-QKI6, 
suppression of wild type Qk was sufficient to increase proliferation within only three days of 
suppression (Fig. 2.14b and 2.15a). The greatest effect was observed in cells overexpressing 
MYB-QKI, despite a similar or lower degree of suppression of Qk in these cells compared to 
those over-expressing eGFP or MYBtr. We did not observe increased proliferation within three 
days in cells expressing eGFP, though we did observe a mild increase on day 5 (Fig. 2.15b). 
These data suggest MYB-QKI overexpression and QKI suppression exert cooperative functional 
effects. 
Suppression of Qk by shRNAs in mNSCs expressing MYB-QKI6 led to differential expression of 
309 genes relative to shLacZ (q<0.25, Table 2.6). QKI has been previously reported to regulate 
expression of micro-RNAs (A. J. Chen et al., 2012; Y. Wang, Vogel, Yu, & Richard, 2013), and 
we also observed upregulation of 10 miRNAs with suppression of wild-type Qk, including 
Mir717 (Table 2.7). The mouse Qk isoform 7 is predicted to contain a miRNA regulatory 
element (MRE) for Mir717 (Ji et al., 2013).  
Angiocentric Gliomas exhibit molecular effects consistent with QKI suppression. In mNSCs, we 
defined a signature consisting of the 50 genes whose expression was most correlated with Qk 
suppression (Fig. 2.15c). This signature was significantly enriched in Angiocentric Gliomas 
relative to normal brain (p<0.0001, Fig. 2.14c).  
Taken together, our data suggest three mechanisms through which the MYB-QKI rearrangement 
contributes to oncogenicity (Fig. 2.16). First, the alteration results in proximal translocation of 
H3K27ac enhancers on 3’QKI towards the MYB promoter, resulting in MYB promoter activation. 
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Second, the MYB-QKI fusion protein that is expressed is oncogenic, functions as a transcription 
factor, and exhibits the ability to bind to and activate the MYB promoter, resulting in an auto-
regulatory feedback loop. Third, hemizygous loss of QKI results in suppression of QKI, which 
functions as a tumor suppressor gene. Thus disruption of both MYB and QKI appear to contribute 
to tumor formation in a co-operative manner. 
Discussion 
We describe MYB-QKI as a novel recurrent diagnostic fusion in Angiocentric Glioma. It also 
represents the first example of a single driver translocation of two genes resulting in the aberrant 
expression of an activated oncogenic fusion protein which then participates in an auto-regulatory 
feedback loop, proximal translocation of enhancer elements regulating fusion-gene expression, 
and simultaneous functional loss of a tumor suppressor gene.  
We found MYB-QKI to be a defining event in Angiocentric Glioma. This has important 
implications for treatment and diagnosis of this disease. The tight association of the translocation 
with this histology supports pathologic classification of Angiocentric Glioma as a separate 
biological entity.  We propose that the presence of this fusion should be considered diagnostic of 
Angiocentric Glioma. This could aid in distinction of Angiocentric Glioma from tumors with 
higher potential for recurrence or require further treatment, such as IDH-mutant diffuse gliomas 
or ependymomas. 
MYB-QKI expression was sufficient to reproducibly generate intracranial tumors. Angiocentric 
Gliomas are WHO grade 1 tumors and exhibit a very low mitotic index. Successful models of 
low-grade pediatric or adult gliomas are rare across all histologies. The low penetrance in mNSCs 
(5 tumors in 29 attempts) relative to high-grade glioma models (e.g. EGFRvIII and Ink4a/Arf -/- 
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NSCs) (Bachoo et al., 2002) suggests genetic drivers of low-grade gliomas may be borderline 
sufficient for transformation. 
Although the development of small molecule inhibitors to target MYB directly is likely to be 
challenging, MYB-QKI transcriptional targets such as KIT or CDK6 can be targeted. The 
association of MYB-QKI with H3K27ac enhancer elements also raises the possibility of 
therapeutically inhibiting its effects through indirect mechanisms, such as BET-bromodomain 
(Pratiti Bandopadhayay et al., 2014; Delmore et al., 2011) or CDK7 inhibition (Chipumuro et al., 
2014). 
Adenoid cystic carcinomas harbor MYB-NFIB alterations (D&apos;Alfonso et al., 2014; Marta 
Persson et al., 2009; Stephens et al., 2013). Like MYB-QKI, MYB-NFIB also results in high levels 
of MYB expression, although the mechanism underlying this, the functional role of NFIB, and 
oncogenicity of MYB-NFIB remain undefined. 
We observed an additive effect of Qk suppression with MYB-QKI over-expression, confirming 
QKI as a tumor suppressor and suggesting cooperation between its loss and expression of MYB-
QKI. Recent studies indicate a diversity of roles for QKI in cancer, including altered splicing 
events (Danan-Gotthold et al., 2015) and a role in epithelial-mesenchymal transition via 
regulation of circular RNAs (Conn et al., 2015). QKI regulates expression of genes implicated in 
cancer (Lu et al., 2014), and microRNA processing (Ji et al., 2013). Further investigation is 
required to evaluate mechanisms of cooperativity between QKI suppression and MYB-QKI 
expression.  
Angiocentric Gliomas exhibit haploinsufficiency of QKI while GBMs demonstrate biallelic loss. 
One explanation may be that complete loss of QKI exerts negative selection in the developing 
brain. This is supported by the essential role of QKI in oligodendrocytic differentiation. 
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Haploinsufficiency may also account for the lower-grade nature of Angiocentric Glioma 
compared to GBM. 
Pediatric tumors are characterized by simple genomes with single driver alterations (Crompton et 
al., 2014; Kieran et al., 2012). Our findings that one rearrangement contributes to oncogenicity 
through multiple mechanisms may be applicable to a large number of pediatric tumors. 
Materials and Methods 
Ethics statement 
Ethics approval was granted by relevant human IRB and/or animal research committees (IACUC) 
of Dana-Farber Cancer Institute (DFCI), Boston Children’s Hospital, The Broad Institute and 
Children’s Hospital of Philadelphia (CHOP). IRB approval from all institutions was obtained, and 
all patients provided informed consent prior to collection of samples or were analyzed as de-
identified samples with specific IRB waiver of informed consent. 
Whole-genome sequencing and processing 
PLGGs and normal controls from CBTTC/CHOP and DFHCC/PLGA Consortium were 
sequenced at BGI@CHOP, and The Broad Institute of MIT and Harvard. DNA was randomly 
fragmented, and libraries prepared for paired-end sequencing on an Illumina HiSeq 2000. 
Sequencing files from recently published PLGG datasets were accessed (D. T. W. Jones et al., 
2013; J. Zhang et al., 2013). Read pairs were aligned to reference genome hg19 (Build 37) using 
the Burrows-Wheeler Aligner (bwa) with options −q 5 −l 32 −k 2 −o 1 (H. Li & Durbin, 2009). 
Reads were sorted by coordinates, normalized, cleaned and duplicates were marked using 
SAMtools and Picard. Base quality score assignments were recalibrated to control for biases due 
to flow cell, lane, dinucleotide context and machine cycle using the Genome Analysis Toolkit 
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(GATK) (McKenna et al., 2010). Copy-number alterations were evaluated using SegSeq (Chiang 
et al., 2009). GISTIC2 was used to identify recurrent copy-number alterations (Beroukhim et al., 
2007; Beroukhim et al., 2010; Zack et al., 2013). Somatic point mutations and short indels were 
called using Mutect (Cibulskis et al., 2013) and IndelLocator, and visual inspection in IGV 
(Robinson et al., 2011). Mutsig (version 2.0) (Lawrence et al., 2014) was applied to detect 
significantly recurrent mutations. Rearrangements and breakpoints were identified using dRanger, 
BreakPointer (Yotam Drier et al., 2013) and visual inspection. All analyses were performed 
within Firehose (M. A. Chapman et al., 2011). This work was conducted by our collaborating lab, 
Rameen Beroukhim and Keith Ligon at Dana-Faber Cancer Institute.    
RNA-sequencing and analysis pipeline 
Following RNA extraction (RNeasy, Qiagen), library construction was performed using a non-
strand specific Illumunia TruSeq protocol. Flowcell cluster amplification and sequencing were 
performed according to the manufacturer’s protocols using HiSeq 2000/2500, with a 76 bp 
paired-end run including an eight-base index barcode read. RNA-sequencing files were 
downloaded from published datasets (D. T. W. Jones et al., 2013; J. Zhang et al., 2013). RNA-seq 
bam files were transformed to fastq files using the Picard SamToFastq algorithm. Raw paired-end 
reads were aligned to the reference genome hg19 and preprocessed using PRADA (Pipeline for 
RNA-sequencing Data Analysis) (Torres-García et al., 2014). We used PRADA within Firehose 
to determine gene-expression levels, exon expression levels, quality metrics, and for detection of 
fusion transcripts. BAM files were also assessed by visual inspection. This work was conducted 
in collaboration with Rameen Beroukhim and Keith Ligon’s labs at Dana-Faber Cancer Institute.   
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Array CGH 
DNA was extracted from archival FFPE samples and aCGH performed as previously described 
(Craig et al., 2012; Ramkissoon et al., 2013). GC-normalized copy-number data was cleaned of 
known germ-line copy-number variations and circular Binary Segmentation was used to segment 
the copy-number data (α = 0.001, undo.splits = sdundo, undo.SD = 1.5, minimum width = 5). 
This work was conducted by Rameen Beroukhim and Keith Ligon labs at Dana-Faber Cancer 
Institute. 
Whole exome sequencing 
WES was performed from FFPE samples (without matched control). These samples were used to 
confirm driver alterations identified by the WGS. DNA was extracted using the QIAGEN DNA 
Blood and Tissue kit. Libraries with a 250 bp average insert size were prepared by Covaris 
sonication, followed by double-size selection (Agencourt AMPure XP beads) and ligation to 
specific barcoded adaptors (Illumina TruSeq) for multiplexed analysis. Exome hybrid capture was 
performed with the Agilent Human All Exon v2 (44 Mb) bait set. 
Sequence data were aligned to the hg19 reference genome with the Burrows-Wheeler Aligner 
with parameters [-q 5 -l 32 -k 2 -t 4 -o 1]. Aligned data were sorted, duplicate-marked, and 
indexed with Picard tools. Base-quality score recalibration and local realignment around 
insertions and deletions was achieved with the Genome Analysis Toolkit. 
Mutations were called with MuTect, filtered against a panel of normals, and annotated to genes 
with Oncotator.  Likely germline SNPs were removed by filtering against the Exome Sequencing 
Project (ESP) and Exome Aggregation Consortium (ExAC).  
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This work was conducted by Rameen Beroukhim and Keith Ligon labs at Dana-Faber Cancer 
Institute. 
Histological assignment 
Histologic subtype assignments were according to previously published data. Samples not 
previously published were centrally reviewed and classified by a board-certified neuropathologist 
(K.L.L., S.S, or S.R.) using W.H.O. 2007 criteria. 
MYB FISH  
FISH was performed as previously described (Firestein et al., 2008) using five micron FFPE 
tissue sections and Homebrew probes RP11-63K22 (5’ to MYB; directly labeled in 
SpectrumOrange) and RP11-170P19 (3’ to MYB; directly labeled in SpectrumGreen) that map to 
6q23.3.  MYB status was assessed in 50 tumor nuclei per sample.  A CEP6 aqua probe 
(Invitrogen) mapping to the centromeric region of chromosome 6 was co-hybridized as a control. 
This work was conducted by the Keith Ligon lab at Dana-Faber Cancer Institute. 
Immunohistochemistry 
Diaminobenzidine (DAB), bright-field staining was performed according to standard protocols on 
five-micron thick paraffin sections.  Heat and 10 mM sodium citrate buffer (pH 6.0) were used 
for antigen retrieval for the MYB (Abcam for human tissue, Bethyl Laboratories for mouse 
tissue), OLIG2 (Chemicon) and GFAP (Millipore) antibodies.  Counterstaining for nuclei was 
performed using Mayer’s hematoxylin stain and coverslips were mounted with Permount (Fisher 
Scientific).  Sections from the left occipital pole of a normal adult brain autopsy were used to 
assess MYB levels. This work was conducted by the Keith Ligon lab at Dana-Faber Cancer 
Institute. 
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Analysis of QKI alterations in TCGA samples. 
GISTIC 2.0 analyses were performed across 10,570 tumor samples from 31 lineages from The 
Cancer Genome Atlas (TCGA), as previously described ack 20 (Zack et al., 2013). This work was 
conducted by the Beroukhim lab at Dana-Faber Cancer Institute. 
Analysis of gene expression in normal tissues. 
RNA-sequencing of normal pediatric brain samples was accessed from the BRAINSPAN Atlas of 
the human developing brain and processed as previously described (Bergthold et al., 2015). MYB 
expression levels from RNA-sequencing obtained from normal autopsy tissues were downloaded 
from the GTEx consortium (G. Consortium, 2013). Expression levels were compared using 
ANOVA and t-tests. p-values <0.05 were considered significant. This work was conducted by the 
Beroukhim lab at Dana-Faber Cancer Institute. 
Vector construction and generation of NIH3T3 stable lines  
MYB-QKI5 and MYB-QKI6 constructs were synthesized as Gateway compatible entry clones. 
MYBtr constructs were generated via PCR mutagenesis using MYB-QKI fusions as templates. 
Full-length MYB and QKI constructs were purchased as gateway entry clones from 
PlasmID/DF/HCC DNA Resource Core. MYB-QKI5 and MYB-QKI6, MYBtr, full-length MYB 
and QKI constructs were sub-cloned into a Gateway-compatible N-MYC-tagged pMXs-Puro 
Retroviral Vector (Cell Biolabs). Platinum-E retroviral packaging cells (Cell BioLabs) were used 
to generate retrovirus as per manufacturer protocols. NIH3T3 cells were infected with retrovirus 
containing media for 6 hours and puromycin selection commenced 48 hours post infection. Stable 
expression of MYC-tagged proteins was confirmed via western blot analysis (anti-MYC HRP 
1:5000 (Invitrogen), anti-MYB antibody 1:5000 (Abcam) and anti-QKI 1:1000 (Bethyl Lab).  
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Soft Agar Colony Formation Assays and quantification 
Anchorage-independent growth of NIH3T3 cells was assayed as previously described (A. J. 
Sievert et al., 2013) with the following modifications: NIH3T3 cells expressing each of the MYB-
QKI5, MYB-QKI6, MYBtr, full-length MYB and full length QKI proteins and retroviral vector 
control were plated in 0.7% agar with DMEM and DBS in 96 well plates (in triplicates). Cell 
colonies were allowed to form for two weeks and images were taken. Images were analyzed using 
ImageJ and colonies with area greater than 500 pixels quantified. 
Generation of reporter construct containing MYB promoter and enhancer constructs 
To assess the effect of candidate enhancer regions on MYB promoter activity, the human MYB 
promoter sequence (shown below) was cloned into the pLightSwitch_Prom Vector (Active Motif) 
that contains a multiple cloning site upstream of a Renilla luciferase reporter gene (RenSP) 
without a promoter. The MluI/BglII site on pLightSwitch_Prom Vector was used to clone the 
MYB promoter sequence (Table 2.9) and the MluI site was further used to clone candidate 
enhancer regions upstream of the MYB promoter. The human QKI 3’UTR enhancer sequences 
(hg18 chr6:163920360-163920809 and chr6:163921548-163921972) were synthesized by 
Invitrogen and cloned into the reporter constructs as described above. The LightSwitch™ 
Random Promoter Control 1 (Active Motif) containing a 1 kb non-conserved, non-genic and non-
repetitive fragment from the human genome cloned upstream of the RenSP luciferase reporter 
gene was used as a negative control. A housekeeping gene promoter vector, LightSwitch™ 
ACTB Promoter Control, was used as positive control for all assays. The luciferase reporter 
constructs containing either the MYB promoter or MYB promoter with enhancers were 
transfected into U87 glioma line (or MYB-QKI stably expressing U87 line) using Lipofectamine 
3000 (n=5), or co-transfected with MYB-QKI or vector control into HEK 293s via Lipofectamine 
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2000 (Invitrogen), or in NIH3T3/ MYB-QKI stably expressing NIH-3T3 lines using PolyFect 
(Qiagen). Luciferase activity was quantified 24 hours post transfection using the LightSwitch™ 
Luciferase Assay Reagent (Active Motif) according to the manufacturer’s protocol.  
mim-1 reporter construct generation and MYB transactivation assays Luciferase reporter 
constructs containing a consensus DNA-binding sequence for c-MYB were generated. The 
reporter construct was designed using the core MYB recognition element (MRE) consensus 
sequence PyAAC(G/T)G which is present in the mim-1 gene promoter, a previously described 
MYB target (Ness et al., 1989). Double stranded oligos were generated by annealing primers 
mim-1 forward and mim-1 reverse (Table 2.9). The annealed oligo was ligated into 
pGL4.10[luc2] vector (Promega) digested with XhoI and HindIII. The pRL Renilla Luciferase 
Reporter Vector (Promega E2261) served as an internal control in all assays. The mim-1 reporter 
construct and pRL renilla vector (ratio 30:1) were co-transfected into HEK-293 along with 
indicated fusions or controls via Lipofectamine 2000. Luciferase activity was quantified 24 hours 
post transfection using the Dual-Luciferase Reporter Assay System (Promega) according to 
manufacturer’s protocol.  
Cell lines 
NIH3T3, 293T and U87 MG cell lines were obtained directly from ACTT and not re-
authenticated.  All cell lines were routinely tested (at least every three months) for mycoplasma 
infection. 
Generation of neural stem cells. 
Embryonic murine neural stem cells (mNSC) were derived from C57BL6 wild-type E14.5 dpc 
mouse embryos (purchased from Taconic) as previously described (Reynolds & Weiss, 1992). 
mNSCs were maintained in culture media with 1:1 Dulbecco modified Eagle medium (Gibco) 
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and neural stem cell media (Gibco) supplemented with B27 (Gibco), EGF (02653, Stem Cell), 
FGF (GF003, Millipore), and Heparin (07980, Stem Cell). This work was conducted by the 
Beroukhim lab at Dana-Faber Cancer Institute. 
Overexpression of transcripts in mouse neural stem cells 
293T cells were transfected with 10 μg lentiviral pLEX307 expression vectors (gift from David 
Root, Addgene plasmid #41392) with packaging plasmids encoding PSPAX2 and VSVG using 
Lipofectamine. Lentivirus-containing supernatant was collected 48 hour after transfection, pooled 
and concentrated (ultrafiltration). Target neural stem cells underwent infection using a spin 
protocol (2000rpm for 120 minutes at 30C with no polybrene). Puromycin selection (0.5mcg/ml) 
commenced 48 hours after infection. This work was conducted by the Beroukhim lab at Dana-
Faber Cancer Institute. 
ShQk experiments and proliferation assays 
Lentiviral vectors (pLKO) encoding shRNAs specific for mouse Qk, targeting sequences in the 
first four exons of Qk, and the control shLacZ were obtained from The RNAi Consortium (Table 
9). Lentivirus was produced by transfection of 293T cells with vectors encoding each shRNA 
(10 μg) with packaging plasmids encoding PSPAX2 and VSVG using Lipofectamine (Invitrogen, 
56532).  Lentivirus-containing supernatant was collected 48 hours after  transfection, and 
concentrated. Target mNSC underwent infection using a spin protocol (2000rpm for 120 minutes 
at 30C with no polybrene). Cells were placed into proliferation assays 48 hours after infection. 
This work was conducted by the Beroukhim lab at Dana-Faber Cancer Institute. 
Cell Proliferation Assays 
1000 cells/well were plated in 96-well plates, with five replicates.  Cell viability was measured by 
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assessing ATP content using Cell Titre-Glo (Promega).  Mean r SEM was calculated. This work 
was conducted by the Beroukhim lab at Dana-Faber Cancer Institute. 
Western immunoblotting 
Cells were lysed and subjected to SDS-PAGE gradient gels as previously described (Pratiti 
Bandopadhayay et al., 2014). Blots were probed with antibodies against MYB (ab45150, 
Abcam), QKI (A300-183A, Bethyl Laboratories) and actin (sc-1615, Santa Cruz).  
RNA extraction and Real-Time RT-PCR 
RNA was extracted with the RNeasy kit (Qiagen).  cDNA was synthesized from 1µg RNA using 
High Capacity RNA to cDNA kits (Applied Biosystems).  Real-time RT-PCR was performed as 
previously described (Pratiti Bandopadhayay et al., 2014). Primers for MYB, QKI and E-actin are 
listed in Table 9.  Samples were amplified in triplicate and data analyzed using the ''CT method. 
This work was conducted by the Beroukhim lab at Dana-Faber Cancer Institute. 
Gene-expression analysis of neural stem cells expressing MYB-QKI 
RNA was extracted from three independently generated pools of mNSC expressing one of eGFP, 
MYBtr, MYB-QKI5, MYB-QKI6 or QKItr.  Gene expression profiles were assayed using 
Affymetrix Mouse Gene 2.0 ST microarrays (Affymetrix, Santa Clara, CA). CEL files were 
RMA normalized (Bolstad, Irizarry, Astrand, & Speed, 2003).  Comparative marker selection 
analysis (Gould, Getz, Monti, Reich, & Mesirov, 2006) was performed in GenePattern using 
default settings. Genes with p-value <0.05 and q-value <0.35 were considered significant. GSEA 
was performed using the C2 (CP) gene sets (MSigDB). Genesets with nominal p-values <0.05 
were considered significant. The MYB-QKI signature was defined using the ClassNeighbours 
module of GenePattern (default settings). This work was conducted by the Beroukhim lab at 
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Dana-Faber Cancer Institute. 
Antibody optimization and ChIP-seq 
We systematically determined the antibody and concentrations that produce the highest signal to 
noise ratio for MYB ChIP-seq using our automated ChIP-seq methodology (Etchegaray et al., 
2015; Garber et al., 2012). We tested two MYB antibodies: abcam ab45150 and Sigma 
SAB4501936. Abcam45150 has been previously used to ChIP MYB (Mansour et al., 2014). We 
split the sheared chromatin between 3 ratios of antibody/chromatin (0.5µl, 1 µl and 5 µl of each 
antibody/1,000,000 cells), and performed ChIP-seq as previously described (Garber et al., 2012). 
As a positive control, we included an antibody targeting H3K27ac (Cell Signaling Technologies 
D5E4, optimized at 1 µl/1,000,000 cells). We found 1µl ab45150/1,000,000 cells to be optimal.  
Results from the MYB ChIP-seq were validated in three ways. First, we performed MYB ChIP-
seq in K562 cells and confirmed enrichment at genes reported to be target genes in a prior study 
of these cells (Fig. 2.17) (Bengtsen et al., 2015). Second, we used Homer (Heinz et al., 2010) to 
perform an unbiased motif analysis across peaks identified (peak detection threshold of ) p1-e6)) 
in mNSC over-expressing MYBQKI, and identified MYB motifs to be the most enriched motifs 
across all peaks (p= 1e-681) (Fig. 2.18a). We observed 92% of all peaks (p threshold 1e-6, 
3392/3672 peaks) to contain a MYB motif (Fig. 2.18b, Table 2.10). Enrichment of MYB motifs 
was significantly higher in data generated with the MYB antibody (p= 1e-681) compared to those 
generated from enrichment with H3K27ac (p=1e-25). Third, we compared our results from 
mNSCs to other published MYB ChIP-seq results. We determined whether MYB bound genes 
identified in our study (MYB peaks containing a MYB motif) were overlapping target genes 
reported in these studies, using a Chi-Square test with Yates Correction. We observed significant 
enrichment (p<0.0001; Fig. 2.18c) (Quintana, Liu, O&apos;Rourke, & Ness, 2011; L. Zhao et al., 
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2011). Of 2879 genes identified in our set 20% (Zhao) and 42% (Quintana) were also identified 
in these studies. 
ChIP libraries were indexed, pooled and sequenced on Illumina Hi-seq-2000 sequencers. Raw 
data was aligned to the mouse reference genome MM9 using Picard tools. Raw sequencing data 
was mapped to the reference genome using bowtie2 version 2.2.1 with parameters -p 4 -k 1. 
Peaks were called using MACS version 1.4.2 over an input control. A p-value threshold of 
enrichment of 1E-6 was used. Density of genomic regions was calculated using 
bamliquidator_batch, version 1.1.0. Reads were extended 200-bp and normalized to read-density 
in units of reads per million mapped reads per bp (rpm/bp). To calculate genome-wide overlap, 
all enriched H3K27ac peaks were extended 5kb in each direction, divided into 50 bins, and read 
density was calculated in each bin. Density was normalized to the largest value observed in each 
experiment genome-wide and plotted as a heat map. Peaks and alignments were converted to 
TDFs by IGV tools and visualized by IGV. Bed files of published ChIP-seq data of H3K27ac 
chromatin maps from normal brain (Zhu et al., 2013) were downloaded and visualized in IGV. 
ChIP-seq enriching for H3K27ac was performed on human pediatric low-grade gliomas by 
Active Motif as recently described (Northcott et al., 2014). Analysis was performed as above 
using a p-value threshold of enrichment of 1E-5. Super-enhancer analysis was performed as 
previously described (Chapuy et al., 2013). 
This work was conducted by the Ligon and Beroukhim labs at Dana-Faber Cancer Institute. 
In vivo experiments 
Mouse flank tumor studies with NIH3T3 Stable Cell Lines: NIH3T3 cell lines were injected 
subcutaneously into the flanks of NSG mice (5 mice for each cell line).  Mice were 6-10 weeks of 
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age, with equal representation of male and female mice. Tumor growth was measured biweekly. 
Ellipsoid tumor volume was calculated using the formula: volume = 1/2(length × width2).  
Intracranial mouse injections: Neurospheres were dissociated and resuspended at 100,000 viable 
 immunocompromised ICR-SCID 
mice.  Animals were monitored and sacrificed at the onset of neurological symptoms.  Brains 
were subjected to routine histological analysis.  Tumors were scored as present based on 
identification of atypical cells by a neuropathologist.  4-6 week old, male IcrTac:ICRPrkdc-Scid 
mice from Taconic were used.  A total of 44 mice were used. This MNSC work was conducted by 
the Ligon and Beroukhim labs at Dana-Faber Cancer Institute.  
Mouse injections were not randomized or blinded. Sample size was not predetermined. 
Qualitative assessment of tumorogenicity was the primary outcome measure. Neuropathologists 
were blinded to group allocation. 
Statistical analysis 
For statistical analysis (unless otherwise described), p values were calculated using Fisher’s, T-
tests or Pearson’s as appropriate.  ANOVA with correction was used for comparison of multiple 
groups.  Log-rank (Mantel-Cox) survival analysis was performed for animal studies and Kaplan 
Meier curves generated.  Error bars shown depict standard error of the mean. 
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Tables and Figures 
Table 2.1. PLGGs included in analysis including tumor demographics, method of 
profiling and driver alterations identified.  
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S2.xlsx  
 
Table 2.2. GISTIC amplification peaks 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S3.txt  
 
Table 2.3. GISTIC deletion peaks 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S4.txt  
 
Table 2.4. Differentially expressed genes in neural stem cells expressing eGFP, 
MYBtr or MYB-QKI 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S5.xlsx  
 
Table 2.5. Gene-Set Enrichment Analysis in neural stem cells expressing eGFP, 
MYBtr or MYB-QKI 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S6.xls  
 
Table 2.6. Differentially expressed genes in neural stem cells expressing MYB-QKI 
with shLacZ or shQk 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S7.xlsx  
Table 2.7. miRNAs that are differentially expressed in mNSCs expressing MYB-
QKI following suppression of wild type Qk 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S8.xlsx  
 
Table 2.8. MYB promoter sequence and shQk clones used in experiments 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S9.xlsx  
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Table 2.9. PCR primers used in experiments. 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S10.xlsx  
 
Table 2.10. ChIP-seq peaks (p1e-6) identified following MYB ChIP-seq in mNSC 
over-expressing MYBQKI5. Peaks that contain a MYB binding motif (fragment size 
used in analysis = 200) are shown in the columns labeled MYBL1 or MYB. 
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S11.xls  
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Figure 2.1 
 
Figure 2.1. Significant regions of recurrent copy-number alterations in PLGG. GISTIC q 
values for amplifications (left) and deletions (right) are plotted across the genome. 
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Figure 2.2 
 
Figure 2.2. Genomic analysis of 172 WGS and/or RNA-seq of PLGGs reveals a recurrent 
rearrangement involving MYB and QKI in Angiocentric Gliomas. (a) Driver alterations 
were identified in 154 of 172 PLGGs profiled with WGS and/or RNA-seq. Histological subtypes 
include Pilocytic Astrocytoma (PA). Pilomyxoid Astrocytoma (PMA), Angiocentric Glioma 
(AG), Oligodendroglioma (OD), Diffuse Astrocytoma (DA), Dysembryoplastic Neuroepithelial 
Tumor (DNT), Ganglioglioma (GG), Pleomorphic Xanthoastrocytoma (PXA), and PLGG not 
otherwise specified (NOS). Tumors for which histology is unavailable are designated NA. (b) 
FISH using probes flanking MYB reveal three patterns in PLGG: disomy, MYB rearrangement, 
or 3’ MYB deletion.  Scale bars = 5 microns. (c) Frequency of MYB alterations or MYB-QKI 
rearrangements in Diffuse Astrocytoma and Angiocentric Glioma.  p value represents enrichment 
of MYB-QKI rearrangements in Angiocentric Glioma. MYB-QKI alterations were identified with 
WGS alone (n=1), WGS and RNA-seq (n=2) or RNA-seq alone (n=3). (d) Breakpoints observed 
in MYB and QKI in Angiocentric Gliomas. Sequence across the breakpoints as determined by 
RNA-seq is shown for each rearrangement. (e) Copy-number profiles from WGS data of MYB 
and QKI in three Angiocentric Gliomas. 
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Figure 2.3 
 
Figure 2.3. Co-mut plot of driver alterations identified in 54 PLGGs profiled with WES 
and/or array CGH. 
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Figure 2.4 
 
 
 
Figure 2.4. Alterations of MYB and QKI occur frequently in human cancers. (a) 
Expression of MYB (mean ± SEM) in normal human colon (n=12), breast (n=27), whole blood 
(n=51), esophagus (n=38), skin (n=25), and brain cortex (n=47). (b) MYB immunohistochemistry 
on human adult frontal cortex.  Scale bar = 100 microns (c) MYB immunohistochemistry on 
human adult white matter.  Scale bar = 100 microns (d) Hematoxylin and eosin (H&E) on human 
fetal neural stem cells generated from the ganglionic eminence at 22 weeks gestation.  Scale bar = 
100 microns (e) MYB immunohistochemistry demonstrates positive staining in a subset of cells.  
Scale bar = 100 microns (f) Sagittal section from embryonic 14.5 days post coitus (E14.5) mouse 
brain. Scale bar = 500 microns. (g) H&E of E14.5 ganglionic eminence (ge) including ventricular 
(ge-vz) and subventricular (ge-svz) zones. Scale bar = 50 microns. (h) Immunohistochemical 
analysis for MYB on the E14.5 ganglionic eminence. Scale bar = 50 microns. (i) MYB 
immunohistochemistry demonstrates positive staining in a subset of cells subventricular zone (ge-
svz) but not the ventricular zone (ge-vz). Scale bars = 50 microns. (j) H&E from periventricular 
region of adult mouse brain. Scale bar = 100 microns. (k) Immunohistochemistry for MYB 
demonstrates positive cells (arrows) in the ependymal/SVZ layer. Scale bars = 100 microns. (l) 
(Left panel) Significance of deletions (x-axis) and (middle and right panels) heatmaps indicating 
copy-number profiles of individual tumors, for chromosome 6q of adult Glioblastomas profiled 
by TCGA. (m) Predicted structure of the MYB-QKI fusion protein, with fusion of the C-terminus 
of QKI to truncated MYB. TAD denotes transactivating domain. The C-terminus of QKI includes 
QUA2 domains and undergoes alternate splicing. MYB-QKI5 retains a nuclear localizing 
sequence (NLS) that is lost in MYB-QKI6. Two variants of MYB-QKI are depicted (Short and 
Long) corresponding to the breakpoint of MYB within the rearrangement. 
54 
 
Figure 2.5 
 
 
 
Figure 2.5. MYB-QKI functions as a transcription factor, and its molecular effects are 
observed in Angiocentric Gliomas. (a) MYB-QKI expression signature in mouse neural stem 
cells relative to cells expressing eGFP controls. (b) Heatmap of H3K27ac and MYB-QKI levels 
at MYB-QKI regions. Each row shows +/-5 kb centered on MYB-QKI peaks. These regions are 
rank-ordered by MYB-QKI signal.  Scaled intensities are in units of rpm/bp (c) ChIP-seq binding 
of MYB-QKI to genes included in the MYB-QKI gene expression signature. (d) mim-1 reporter 
induction following transfection of MYBtr, MYB-QKI5,  MYBQKI6 or full length MYB in 293T 
cells. Values shown represent mean of three independent measurements ± SEM. (e) Expression of 
MYB-QKI signature in normal pediatric brain samples, PLGGs without MYB-QKI, or 
Angiocentric Gliomas with MYB-QKI. Values represent mean expression of signature in tumors 
± SEM. Expression of signature within each tumor is the sum of rpkm of each gene in the 
signature.  
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Figure 2.6 
 
 
Figure 2.6. MYB functional assays and related data (a) Identified MYB-QKI binding peaks 
at MYB in mNSC over-expressing MYB-QKI. (b) Expression of MYB, MYBtr, MYB-QKI and 
QKItr in mim-promoter assays (c) Linear increases in mim-1 promoter activity with increases in 
MYB-QKI expression. (d) Enrichment of MYB pathway activation in normal brain, PLGGs 
without MYB-QKI or Angiocentric Gliomas with MYB-QKI. Values represent mean expression 
± SEM 
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Figure 2.7 
 
Figure 2.7. Angiocentric Gliomas exhibit aberrant expression of MYB-QKI due to 
H3K27ac enhancer translocation and an auto-regulatory feedback circuit in which 
MYB-QKI binds to the MYB promoter. (a) MYB RPKM expression levels of MYB-QKI 
tumors (n=5) relative to normal brain (n=10) or BRAF or FGFR driven PLGGs (n=10). Values 
shown represent mean ±  SEM. (b) Exon-specific expression of MYB in Angiocentric Gliomas 
that harbor MYB-QKI relative to PLGGs that harbor BRAF alterations (n=3). (c) H3K27ac 
binding in proximity to MYB (upper) and QKI (lower) in mouse neural stem cells. MACs peaks 
are shown. (d) H3K27ac binding to enhancer elements within MYB and QKI in human frontal and 
temporal lobes (Encode). Values shown depict the mean number of nucleotides that are H3K27ac 
bound (per kilobase) in MYB and QKI across both locations. (e) Predicted H3K27ac enhancer 
elements in MYB-QKI, with translocation of genomic enhancers on 3’QKI within 15kb of 
5’MYB. Enhancer maps shown are derived from Encode data from normal brain (frontal lobe and 
temporal lobe). Q3E1 shows an H3K27ac enhancer present in the Encode data from normal brain 
data. 
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Figure 2.8 
 
Figure 2.8. Human Angiocentric Gliomas exhibit H3K27ac enhancer translocation with 
an aberrant enhancer associated with the MYB promoter. (a) H3K27ac enhancer peaks in 
proximity to MYB and QKI in a BRAF-duplicated Pilocytic Astrocytoma (top) and MYB-QKI 
Angiocentric Glioma (lower). Q3E1 is an enhancer associated with the 3’UTR of QKI. Two 
super-enhancer clusters (Q3SE1 and Q3SE2) are located within 500kb of QKI. Angiocentric 
Gliomas are associated with aberrant enhancer formation at the MYB promoter (M5E1), which is 
not detected in the BRAF driven pilocytic astrocytoma. The breakpoints for the MYB-QKI 
rearrangement are between exons 1-9 MYB and 5-8 QKI. Expression as determined by RNA-
sequencing is depicted for the MYB-QKI Angiocentric Glioma. (b) 3’ QKI associated super-
enhancers (Q3SE1/2) presented in two Angiocentric Gliomas. (c) MYB promoter activation 
following transfection of the MYB-luc construct in U87 cells and U87 cells over-expressing 
MYB-QKI with and without Q3E1 enhancer cloned into MYB-luc construct. Changes in 
luciferase activity of the MYB-luc reporter is shown as mean of three individual replicate 
experiments with n=5. 
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Figure 2.9 
 
 
 
Figure 2.9. H3K27ac enhancer profiling of 3’QKI in a human Angiocentric Glioma. 
H3K27ac peaks are depicted.  
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Figure 2.10 
 
 
 
Figure 2.10. H3K27ac enhancer formation at the MYB promoter in two human MYB-QKI 
Angiocentric Gliomas (top tracks) and a BRAF altered Pilocytic Astrocytoma (lower track).
MYB
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Figure 2.11 
 
 
 
Figure 2.11. Supplementary figures for MYB-QKI assays (a) MYB promoter activation in 
HEK293T and NIH3T3 cells with and without expression of MYB-QKI. (b) Exogenous 
expression of MYB-QKI and MYBtr in NIH3T3 cells and mouse neural stem cells via retroviral 
transduction. (c) Representative OLIG2 and GFAP immunohistochemical analysis of tumors 
from mNSCs overexpressing MYBtr, MYBQKI5, MYB-QKI compared to eGFP controls.  
Positive staining for both OLIG2 and GFAP is observed in a subset of tumors cells in tumors 
generated from MYBtr or MYBQKI5 overexpression, while tumors formed by MYB-QKI6 
overexpression are negative for OLIG2 and have low GFAP expression.  Scale bars=50 microns.  
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Figure 2.12 
 
Figure 2.12. MYB-QKI and MYBtr are oncogenic. (a) In vitro cell proliferation rates of 
mNSCs over-expressing eGFP, MYB-QKI5 (Short) or MYB-QKI6 (Short). Mean of five 
independent pools are depicted. Error bars represent SEM. Representative images intracranial 
mNSC-MYB-QKI6 tumors. (b) Tumor growth following flank injections of NIH3T3 cells 
overexpressing MYB, MYB-QKI5 (Long), MYB-QKI6 (Long) or a vector control. Mean of five 
measurements are depicted. Error bars represent SEM. (c) In vitro cell proliferation of mouse 
neural stem cells which over-express MYBtr or eGFP controls. Mean of five independent pools is 
depicted. Error bars represent SEM. Representative images of intracranial mNSC-MYBtr tumors. 
(d) Tumor growth following flank injections of NIH3T3 cells overexpressing MYB, MYBtr or 
vector control. Mean of five measurements is depicted. Error bars represent SEM. (e)  
Hematoxylin and eosin (H&E) analysis of SCID mouse brain after striatal injections with mNSCs 
expressing eGFP, MYBtr, MYBQKI5 or MYBQKI6.  Scale bars=2.0mm (top) or 50 microns 
(bottom). (f) Kaplan-Meier survival analysis of orthotopic SCID mice injected with mNSCs 
overexpressing MYBtr, MYBQKI5, or MYBQKI6 develop tumors with short latency compared 
to mNSCs expressing eGFP which never developed tumors, p<0.01.    
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Figure 2.13 
 
Figure 2.13 Oncogenic assays of MYB-QKI expressing cells. (a) Number of colonies of 
NIH3T3 cells expressing MYB, MYB-QKI or a vector control in soft agar (Left) and 
representative images (right). NIH3T3 cells over-expressing BRAFV600E are shown as a 
positive control. Mean of three replicate measurements are shown. Error bars represent SEM. (b) 
Table of tumor penetrance from both 3T3 and mNSC models with overall p-value<0.001. 
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Figure 2.14 
 
Figure 2.14. MYB-QKI disrupts expression of QKI, a tumor suppressor gene. (a) Exon 
specific expression of  in Angiocentric Gliomas (n=5) relative to BRAF-driven PLGGs (n=5). 
Values represent mean ± SEM. RNA-sequencing data of Exon 8 of QKI revealed a high number 
of duplicate reads and thus is not shown. (b) Cell proliferation of mouse neural stem cells 
expressing MYBtr, MYB-QKI5, MYB-QKI6 or eGFP control with suppression of wild-type Qk. 
Values represent mean of four independent experiments ± SEM. (c) Expression of signature 
within each tumor is the sum of rpkm of each gene in the signature. 
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Figure 2.15 
 
Figure 2.15. QKI knockdown in MNSCs and supplementary assays (a) Suppression of wild 
type Qk in mouse NSC expressing MYB-QKI following infection with shQKI vectors (or shLacZ 
control). (b) Proliferation of mouse NSC over-expressing eGFP, MYBtr or MYB-QKI with 
suppression of wild type Qk over five days in Pool 4 (Values represent mean of 5 replicate 
measurements with SEM). Expression of wild type Qk relative to shLacZ control is shown. (c) 
shQK signature defined following suppression of wild type Qk in mouse neural stem cells that 
over-express MYB-QKI6. 
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Figure 2.16 
 
Figure 2.16. The MYB-QKI rearrangement contributes to oncogenesis through at least 
three mechanisms. The MYB-QKI rearrangement disrupts both MYB and QKI, resulting in 
hemizygous deletion of 3’MYB and 5’ QKI. This results in proximal translocation of H3K27ac 
enhancers on 3’QKI towards the MYB promoter, resulting in MYB promoter activation (i). The 
MYB-QKI fusion protein that is expressed is oncogenic, functions as a transcription factor, and 
exhibits the ability to bind to and activate the MYB promoter, resulting in an auto-regulatory 
feedback loop (ii). Hemizygous loss of QKI results in suppression of QKI expression, which 
functions as a tumor suppressor gene (iii).  
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Figure 2.17 
 
Figure 2.17. Validation of MYB ChIP-seq. MYB binding to reported MYB target genes in 
K562 cells. ChIP-seq enrichment was performed using Abcam 45150.  
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Figure 2.18 
 
Figure 2.18. Validation of MYB DNA binding motif in MYB-QKI (a) Top four enriched DNA 
binding motifs in MYB ChIP-seq peaks obtained from mNSC over-expressing MYB-QKI. (b) 
MYB DNA-binding motifs. (c) Venn diagrams showing overlap of identified MYBQKI peaks 
identified (p threshold 1e-6) compared to those reported in Zhao et al and Quintana et al. p values 
shown were calcuated by Chi Square with Yates correction.  Of 2879 genes identified in our set 
20% (Zhao) and 42% (Quintana) were also identified in these studies. 
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CHAPTER 3: RAF1 gene fusions in pediatric low-grade gliomas 
show differential response to targeted therapeutics based on 
dimerization profiles. 
 
Summary 
Pediatric low-grade gliomas (PLGGs) are associated with dysregulated MAPK signaling, most 
commonly driven by gene fusions involving BRAF. This has led to the initiation of several 
clinical trials utilizing RAF and MAPK targeted therapeutics for PLGGs. While the majority of 
infratentorial PLGGs harbor BRAF gene fusions, a small number have been recently found to 
harbor gene fusions involving another RAF isoform, CRAF/RAF1. In this study, we 
unexpectedly found distinct responsiveness of RAF1 fusions to clinically relevant RAF-targeted 
therapies. We show that CRAF fusions, QKI-RAF1 and SRGAP3-RAF1 are oncogenic in 
multiple cellular contexts through activation of the MAPK and PI3K signaling pathways. While 
both BRAF and CRAF fusions resist suppression with first-generation RAF inhibitor 
Vemurafenib, only BRAF fusions exhibited growth inhibition and reduced MAPK signaling in 
response to second-generation paradox breaking RAF inhibitor PLX8394. We further 
demonstrate that unlike BRAF fusions, RAF1 fusions retained robust homo- and hetero-
dimerization in the presence of PLX8394 and disrupting dimerization through point mutations or 
with the novel LY3009120 RAF dimer inhibitor significantly reduced the oncogenicity of RAF1 
fusions. Intriguingly, using dimerization point mutants of QKI-RAF1, we found that altering the 
dimerization domains in N-terminal QKI had a significantly larger effect on oncogenic phenotype 
compared to disruption of C-terminal RAF1 dimerization. This suggests a previously 
unrecognized role for N-terminal partner protein in mediating dimerization of RAF1 gene fusions 
and potential resistance mechanism to paradox breaker RAF inhibitors. Finally, we tested 
therapeutic targeting of downstream MAPK pathway in RAF1 fusions using the MEK inhibitor, 
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Trametinib and observed partial suppression of tumor growth. Using combinatorial targeting of 
both MAPK and PI3K pathway was more successful in suppressing RAF1 fusion induced tumor 
growth. 
Introduction 
As the most common set of brain tumors in children (Kleihues et al., 2002), pediatric low-grade 
gliomas (PLGGs) represent a heterogeneous group of tumors with histologies ranging from 
pilocytic astrocytomas (WHO grade I) to diffuse fibrillary astrocytomas (WHO grade II). Despite 
having good overall prognosis, children with PLGGs often suffer from long-term treatment 
related and tumor related complications (Sievert & Fisher, 2009).  Mutations involving BRAF, 
mostly the KIAA1549-BRAF gene fusion that activates the MAPK pathway, have predominantly 
been associated with pilocytic astrocytomas (PAs) (Jacob et al., 2009; Sievert et al., 2009; A. J. 
Sievert et al., 2013). However, recent sequencing studies have discovered the occurrence of rare 
CRAF (or RAF1) gene mutations, QKI-RAF1 and SRGAP3-RAF1, in PLGGs (D. T. Jones et al., 
2009; J. Zhang et al., 2013). But the prevalence, oncogenic mechanism of action and sensitivity 
of the novel RAF1 gene fusions to targeted therapeutics remains unknown.  
Whole-genome sequencing studies first detected QKI-RAF1 as an infrequent gene fusion in 
pilocytic astrocytomas (J. Zhang et al., 2013) whereas SRGAP3-RAF1 was first reported as a 
tandem duplication event that leads to a copy number gain at chromosome 3p25 in a pilocytic 
astrocytoma (D. T. Jones et al., 2006; D. T. Jones et al., 2009). While SRGAP3-RAF1 has been 
reported to activate the MAPK pathway, no further studies have been conducted on these RAF1 
gene fusions to assess response to therapy. Another RAF1 gene fusion, called FYCO1-RAF1, has 
also been detected in PLGGs (J. Zhang et al., 2013). These studies add further complexity to the 
molecular classification schemes that are currently being developed for PLGGs, as there seems to 
be genetic diversity even within the same histologic subtype. 
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To study the PLGG-associated RAF1 fusions, QKI-RAF1 and SRGAP3-RAF1, we performed 
cellular, molecular, biochemical and in vivo assays to test oncogenic mechanisms activated by 
these fusions. Like the BRAF fusions, RAF1 fusions also activate the MAPK signaling pathway 
and also a parallel PI3K/mTOR pathway. While first-generation RAF inhibitors such as 
vemurafenib do not target PLGGs with BRAF fusion, second-generation PLX8394 inhibits 
BRAF fusion’s oncogenicity (A. J. Sievert et al., 2013). Interestingly, we found the RAF1 fusion 
to be unresponsive to both first- and second-generation RAF inhibitors. Upon assessing their 
dimerization profile, we found dependence of RAF1 fusions on both homodimerization with itself 
and heterodimerization with wild type RAF proteins. These protein-protein interactions remained 
resistant to second-generation RAF inhibitors but were sensitive to and modified by novel RAF 
dimer inhibitor, LY3009120. We also tested the sensitivity of RAF1 fusions to MAPK and 
PI3K/mTOR targeted therapeutics as single-agent and combinatorial therapies.  
Results 
QKI-RAF1 and SRGAP3-RAF1 fusions are oncogenic proteins that activate the MAPK and 
PI3K signaling pathways 
QKI-RAF1 contains exons 1-3 of the N-terminus of QKI, which belongs to a family of RNA 
binding proteins known as the signal transduction and activation of RNA (STAR) proteins (Fig. 
3.1a). In this fusion, QKI loses part of its RNA binding domain from the C terminus but retains 
an intact homodimerization domain at the N-terminus (Vernet & Artzt, 1997). While QKI is 
known to regulate glial development and myelination in the CNS (Friedrich, 1974), loss of QKI 
has been detected in glioblastomas (Lawrence et al., 2014; Z. Z. Li et al., 2002; Yin et al., 2009), 
angiocentric gliomas (Bandopadhayay et al., 2016), prostate cancer (Y. Zhao et al., 2014), lung 
cancer (Zong et al., 2014) and gastric cancer (Bian et al., 2012).  
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CRAF/RAF1 is a serine/threonine kinase that was first discovered as the v-raf oncogene in the 
transforming mouse sarcoma virus (Rapp et al., 1983; Rapp & Todaro, 1978). Both QKI-RAF1 
and SRGAP3-RAF1 fusions have lost the N-terminal non-catalytic domain of RAF1 and the 
functional kinase domain is retained (Fig. 3.1a) suggesting auto-activation of the kinase activity. 
Several studies have shown that loss of N-terminal domains of RAF1 can lead to oncogenic 
activation and tumorigenesis (Cutler et al., 1998; Heidecker et al., 1990; Stanton, Nichols, 
Laudano, & Cooper, 1989) but few studies have implicated oncogenic mechanism of RAF1 gene 
fusions by focusing on both gene fusion partners. 
SRGAP3 is a member of the SLIT-ROBO Rho GTPase-activating protein (srGAP) family and is 
involved in several neurodevelopmental processes via regulation of actin cytoskeleton dynamics 
(Bacon et al., 2009; Carlson et al., 2011). SRGAP3 possess an N-terminal Fes-CIP4 homology 
(FCH) domain and a coiled-coil domain (together called F-BAR domain), a central Rho-GAP 
domain and C-terminal SH3 domain (Wong et al., 2001). The SRGAP3-RAF1 gene fusion retains 
the FCH domains of SRGAP3 that has been suggested to have dimerization properties (Henne et 
al., 2007) whereas the other C-terminal domains are lost. This also suggests a potential role for 
the N-terminal fusion protein SRGAP3 to contribute to fusion dimerization, which is a critical 
component for activation of RAF1 kinase activity. 
While RAF1 gene fusions are rare genetic events in PLGGs, the overall prevalence is not known 
due to lack of genomic studies that can enrich for such fusions. However, the occurrence of 
different RAF1 gene fusions in adult cancers along with PLGGs (Fig. 3.1b) highlights the 
growing importance of studying RAF1 gene fusions and their therapeutic targeting. Majority of 
the RAF1 fusions listed in the table have lost the N-terminal auto-inhibitory domains of RAF1 
thereby supporting the hypothesis that RAF1 kinase could be constitutively active in RAF1 
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fusions, thereby driving tumorigenesis. Therefore, we sought to test the oncogenic potential and 
mechanism of action of the PLGG associated RAF1 fusions- SRGAP3-RAF1 and QKI-RAF1.  
To study these fusions, we stably expressed SRGAP3-RAF1 and QKI-RAF1 in two different 
heterologous cell model systems: NIH3T3 cells and p53-null primary mouse astrocyte cells 
(PMAs) (J. Zhang et al., 2013). To assess the oncogenic potential of RAF1 gene fusions, we 
performed soft agar assays and measured colony formation. Over-expression of QKI-RAF1 and 
SRGAP3-RAF1 in NIH3T3 cells and PMAs was sufficient to drive significant anchorage 
independent growth in soft agar compared to vector controls (Fig. 3.1c and 1e, p-value<0.05 to 
0.001).  
Upon assessing downstream signaling pathways in the stable NIH3T3 cell lines, we found the 
mitogen associated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K) signaling 
pathway to be aberrantly activated by QKI-RAF1 and SRGAP3-RAF1 as monitored by elevated 
phosphorylated MEK land AKT/S6 levels, respectively (Fig. 3.1d). The MAPK signaling 
pathway was aberrantly activated by QKI-RAF1 and SRGAP3-RAF1 in PMA cell lines (Fig. 
3.1f). The differences in aberrant activation of MAPK and PI3K pathway in the NIH3T3 cell 
lines versus the PMA cells is likely due to variation in signaling programs in different cellular 
contexts.  
To test tumor-forming capacity in vivo, we injected stable NIH3T3 cell lines expressing QKI-
RAF1 and SRGAP3-RAF1 into flanks of NSG mice. Both RAF1 fusions formed robust flank 
xenograft tumors compared to vector controls (Fig. 3.1g, p-value<0.001). Using the stable PMA 
cell lines, we performed intra-cranial injections into NSG mice brains. Interestingly, QKI-RAF1 
and SRGAP3-RAF1 expressing PMAs but not vector control, caused tumors leading to poor 
survival in all mice injected with RAF1 fusion expressing PMAs (Fig. 3.1h, p-value<0.01). These 
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findings demonstrate that QKI-RAF1 and SRGAP3-RAF1 are driver oncogenes in PLGGs as they 
drive robust oncogenesis in different cell model systems.  
First- and second-generation RAF inhibitors do not suppress QKI-RAF1 and SRGAP3-
RAF1 
First generation RAF inhibitors such as vemurafenib (PLX4032) (Bollag et al., 2010) have shown 
clinical efficacy and survival benefit in melanomas that harbor the most commonly found BRAF 
mutation, BRAF V600E, that changes valine to glutamate at residue 600 in exon 15 (P. B. 
Chapman et al., 2011; Flaherty et al., 2010; Sosman et al., 2012). However, we have previously 
shown that PLGGs with BRAF fusions such as KIAA1549-BRAF also demonstrate resistance to 
PLX4720 (research analog of vemurafenib) via paradoxical activation of the MAPK pathway (A. 
J. Sievert et al., 2013) (Fig. 3.2). We also demonstrated that KIAA1549-BRAF was responsive to 
a second-generation RAF inhibitor, PLX8394, which is termed as a ‘paradox breaker’ due to 
evasion of paradoxical MAPK pathway activation (A. J. Sievert et al., 2013; C. Zhang et al., 
2015). Although several RAF inhibitors are currently being tested in clinical trials for PLGGs, 
there are no existing studies examining how the RAF1 gene fusions would respond to these first- 
and second-generation RAF inhibitors, compared to BRAF fusions.  
We tested the response of NIH3T3 and PMA cell models expressing QKI-RAF1 and SRGAP3-
RAF1 to increasing concentrations of first- and second-generation RAF inhibitors, PLX4720 and 
PLX8394, respectively. In NIH3T3 lines expressing QKI-RAF1, both the first- and second-
generation inhibitors caused paradoxical activation of MAPK pathway as evident by elevated 
phospho-MEK and phospho-ERK levels with increasing drug concentrations (Fig. 3.3a). 
Interestingly, we observed a partial suppression of phospho-S6 signal at high concentrations of 
the drugs despite paradoxical phosphorylation of AKTT308 with PLX8394 (Fig. 3.3a), suggesting 
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some downregulation of PI3K pathway. We also observed similar paradoxical activation of 
MAPK pathway in stable PMA cell lines with QKI-RAF1 (Fig. 3.3e). However, both RAF 
inhibitors failed to suppress QKI-RAF1 driven soft agar colony growth and instead showed 
paradoxical increase in oncogenic growth (Fig. 3.3b, f). 
 SRGAP3-RAF1 expressing NIH3T3 lines showed a similar paradoxical increase in MAPK 
pathway with increasing PLX4720 and PLX8394 concentrations (Fig. 3.3c) with some PI3K 
pathway suppression. Again, there was no decrease in SRGAP3-RAF1 driven soft agar colony 
growth in the presence of the RAF inhibitors in both NIH3T3 cells and PMAs (Fig. 3.3 d, g, 
respectively). These findings show a direct correlation of drug-induced paradoxical activation of 
the MAPK pathway in RAF1 fusion cells and unresponsiveness to first- and second-generation 
RAF inhibitors. Even though the PI3K pathway was affected by high RAF inhibitor 
concentrations by some unknown mechanism, lack of suppression of soft agar growth suggests 
that it could be secondary to MAPK pathway in driving the RAF1 fusion cells.  
RAF1 fusions function as homodimers and heterodimers with B/CRAF that are resistant to 
second-generation paradox breakers  
The chemical structure of PLX8394 has been shown to prevent RAF dimerization by interacting 
with residues on the regulatory spine of RAF kinases (C. Zhang et al., 2015) but our findings 
suggest that RAF1 fusions respond differentially compared to wild type proteins. Since RAF 
homodimerization and heterodimerization is important for activation of RAF kinase activity 
(Rajakulendran, Sahmi, Lefrancois, Sicheri, & Therrien, 2009) and the oncogenic kinase activity 
of KIAA1549-BRAF fusion has been attributed to homodimerization (A. J. Sievert et al., 2013), 
we hypothesized that the RAF1 gene fusions could be functioning via homodimerization and/or 
heterodimerization dependent activation. The presence of dimerization domains in both QKI (Ali 
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& Broadhurst, 2013; T. Chen & S. Richard, 1998)/ SRGAP3 (Henne et al., 2007) and RAF1 
(Hatzivassiliou et al., 2010; Rajakulendran et al., 2009) suggests that both fusion partners in 
RAF1 fusions could be contributing to homodimerization and/or heterodimerization. Therefore, 
we characterized how such protein-protein interactions could be responsible for oncogenic 
activity and RAF inhibitor resistance in RAF1 gene fusions.  
To test the dimerization potential of RAF1 fusions, we assessed the ability of QKI-RAF1 to 
interact as homodimers and also heterodimerize with wild type BRAF, CRAF, QKI and truncated 
QKI (exons 1-3) by using myc- and flag-tagged constructs. Upon immunoprecipitation (IP) of 
QKI-RAF1 with a Myc antibody, we detected QKI-RAF1 protein-protein interactions with QKI-
RAF1 itself, wild type BRAF, CRAF, QKI and truncated QKI but not the vector control (Fig. 
3.4). Similarly, SRGAP3-RAF1 also shows home-dimerization and heterodimerization with wild 
type BRAF, CRAF (Fig. 3.5). These results suggest that dimerization may underlie the activation 
and functionality of RAF1 fusion kinases.  
Previous studies have shown that first-generation RAF inhibitor vemurafenib induces paradoxical 
activation of MAPK pathway by binding to one protomer of wild type RAF dimer and trans-
activating the other uninhibited RAF protomer (Hatzivassiliou et al., 2010). Modifications to 
structure of vemurafenib resulted in PLX8394 that has been shown to evade paradoxical 
activation in wild type BRAF and BRAFV600E mutant cells (C. Zhang et al., 2015). Since 
PLX8394 does not suppress RAF1 fusion mediated oncogenic growth, we next evaluated whether 
this unresponsiveness is due to inability of the drug to bind and disrupt RAF1 fusion’s protein-
protein interactions. We found that PLX8394 was unable to disrupt QKI-RAF1 mediated homo-
dimerization and heterodimerization with wild type B/CRAF or QKI (Fig. 3B). This is in contrast 
to PLX8394 disrupting the homodimerization of KIAA1549-BRAF fusion (Fig. 3.4c), where we 
have previously shown that the paradox breaker (PLX8394) is functional in suppressing 
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oncogenicity (A. J. Sievert et al., 2013). This suggests a correlation between dimer inhibition in 
the presence of PLX8394 and responsiveness to drug, thereby rationalizing why clinically 
relevant RAF inhibitors do not suppress CRAF fusions but BRAF fusions can be suppressed with 
paradox breaker drugs.  
RAF1 fusions activate oncogenic signaling in a dimerization-dependent manner  
QKI-RAF1 and SRGAP3-RAF1 both retain the active RAF1 kinase domain, including specific 
residues critical for forming the dimer interface of RAF1 (Bollag et al., 2010; Rajakulendran et 
al., 2009). Point mutations in key dimer interface residues of RAF1 (R401H) have been shown to 
disrupt RAF1 dimerization with little to no effect on basal kinase activity (Freeman, Ritt, & 
Morrison, 2013a, 2013b). We assessed whether mutating the critical dimerization residues of 
RAF1 would disrupt the fusion’s dimerization capacity using QKI-RAF1 (denoted as QKI-
RAF1R401H). In co-IP assays, we observed that QKI-RAF1 homodimerization was unaffected with 
QKI-RAF1R401H (Fig. 3.6a) indicating that RAF1 fusion partner was not necessary for 
dimerization. QKI-RAF1R401H showed decreased dimerization with wild type BRAF and CRAF 
proteins (Fig. 3.6b, c) and also with wild type QKI (Fig. 3.6d) by unknown mechanisms. These 
findings with the R401H mutants suggest that while RAF1 dimer interface is critical for 
interaction with wild type B/CRAF, it is only partly responsible for QKI-RAF1 mediated 
dimerization.  
We next assessed the dimerization motif of the N-terminal partner, QKI. The N-terminal QUA1 
region of QKI contains dimerization elements and a point mutation E48G in the key dimerization 
residue results in disruption of QKI dimers and RNA binding function (Ali & Broadhurst, 2013; 
Beuck, Qu, Fagg, Ares, & Williamson, 2012). This mutation (QKIE48G-RAF1) robustly decreased 
homodimerization with QKI-RAF1 (Fig. 3.6a) and heterodimerization with CRAF and QKI (Fig. 
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3.6 c, d). These data suggest a critical role for the QKI fusion partner in mediating dimerization 
and downstream functionality of QKI-RAF1. Even CRAF interaction was affected with QKIE48G-
RAF1 whereas CRAF interaction is expected to be mediated by RAF1 and not QKI. This hints at 
the possibility that QKI-RAF1 forms homodimers followed by CRAF binding to form complex 
oligomers but this needs to be tested further. It could be possible that due to loss of QKIE48G-
RAF1 homo-dimerization, CRAF does not interact with QKIE48G-RAF1 (Fig. 3.6 c).  
Next, we tested double point mutants with mutations in dimerization residues of both QKI and 
RAF1 (denoted as QKIE48G-RAF1R401H). In co-IP assays, QKIE48G-RAF1R401H double mutant 
showed severe loss of interaction with QKI-RAF1, wild type BRAF, CRAF and QKI (Fig. 3.6). 
Overall, these results suggest that the N-terminal fusion partner (QKI) primarily mediates RAF1 
fusion’s dimerization with some contribution of RAF1 as mutating dimerization residues in both 
QKI and RAF1 results in robust loss of all protein-protein dimerizations.  
We further tested the effect of QKI, RAF1 and double dimer mutants on oncogenic signaling and 
tumorigenic phenotype of QKI-RAF1. We transduced mouse astrocyte cells with various dimer 
mutant constructs and tested downstream MAPK signaling. As compared to QKI-RAF1, QKI-
RAF1R401H showed similar phospho-MEK, phospho-ERK and phospho-S6 levels whereas 
QKIE48G-RAF1 and QKIE48G-RAF1R401H had robust reduction in MAPK signaling (Fig. 3.6e). 
QKIE48G-RAF1R401H also demonstrated reduction in phospho-S6 beyond the basal level. These 
results strongly suggest the importance of QKI fusion partner driving QKI-RAF1 dimerization 
and subsequent activation of oncogenic MAPK signaling.  When tested in soft agar assays for 
tumorigenic potential, QKI-RAF1R401H showed a decrease in colony formation but was not 
significantly different from QKI-RAF1 (Fig. 3.6f). In contrast, QKIE48G-RAF1 and QKIE48G-
RAF1R401H displayed little anchorage-independent growth compared to QKI-RAF1 (Fig. 3.6f, p-
value <0.01), demonstrating that QKI-RAF1 driven soft agar growth is primarily dependent on 
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QKI dimerization residues. Hence, disruption of QKI-driven dimerization would be required to 
suppress oncogenic properties of QKI-RAF1 expressing PLGGs.  
We also evaluated effects of R401H mutation on SRGAP3-RAF1. MAPK signaling was 
decreased in mouse astrocyte cells expressing SRGAP3-RAF1R401H as compared to SRGAP3-
RAF1 but was more than baseline vector control (Fig. 3.5b). In soft agar assays SRGAP3-
RAF1R401H showed a significant decrease in oncogenic colony formation indicating the role RAF1 
dimerization motif in SRGAP3-RAF1 (Fig. 3.5c).  
N-terminal fusion partner looses functionality in RAF1 fusions 
The loss of RNA binding function of QKI has been associated with increased oncogenicity in 
adult glioblastomas (A. J. Chen et al., 2012) and lung cancers (Zong et al., 2014) and decreased 
QKI expression has been correlated with occurrence of prostate cancer (Y. Zhao et al., 2014) and 
gastric cancer (Bian et al., 2012). Since part of the QKI RNA binding motif is retained in QKI-
RAF1, we tested whether QKI has lost its RNA binding function in QKI-RAF1 and how that 
could correlate with oncogenicity in PLGGs. We performed UV cross-linking experiments where 
well-known RNA targets of QKI, myelin basic protein (MBP) and early growth response gene-2 
(EGR-2) (Galarneau & Richard, 2005), were radiolabeled and incubated with vector control, full 
length QKI and QKI-RAF1. Compared to negative vector control, QKI bound to both RNA 
targets but QKI-RAF1 failed to bind either RNA target (Fig. 3.6g, 3.7) thereby indicating that 
QKI-RAF1 has lost RNA binding function. We have previously shown that partial loss of QKI 
expression in MYB-QKI expressing PLGGs leads to increased oncogenicity (Bandopadhayay et 
al., 2016) and such a mechanism could also be possible in QKI-RAF1 expressing tumors. These 
results suggest the possible contribution of QKI loss of function in mediating QKI-RAF1 
oncogenicity.  
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SRGAP3 has also been reported as a tumor suppressor-like gene with low expression in breast 
cancer cells (Lahoz & Hall, 2013). Loss of the functional Rho-GTPase domains in SRGAP3-
RAF1 suggests a loss of function for SRGAP3, similar to QKI in QKI-RAF1. This needs to be 
further explored as a common theme for N-terminal fusion partners contributing to RAF1 
fusion’s oncogenicity. 
RAF1 fusions are sensitive to LY3009120, a RAF dimer inhibitor 
Since dimerization is a key component of RAF1 fusion’s oncogenicity, we investigated the effect 
of novel dimer inhibitor LY3009120 that has recently shown efficacy in suppressing mutant 
BRAF dimers in adult cancers (S. H. Chen et al., 2016; Henry et al., 2015; Peng et al., 2015). 
LY3009120 is a pan-RAF inhibitor with potent anti-tumor effects and does not result in 
paradoxical activation unlike vemurafenib. In stable NIH3T3 cells, LY3009120 showed potent, 
dose-dependent inhibition of both MAPK and PI3K pathways driven by QKI-RAF1 and 
SRGAP3-RAF1 (Fig. 3.8a). Even low doses of LY3009120 were successful at suppressing 
anchorage independent growth driven by RAF1 fusions in NIH3T3 cells (Fig. 3.8b, p-
value<0.001). Similar suppression of MAPK pathway was observed at high concentrations of 
LY3009120 in RAF1 fusion expressing mouse astrocyte cell lines (Fig. 3.8c) whereas PI3K 
pathway was not abolished as seen in NIH3T3 cell lines. Nevertheless, LY3009120 potently 
suppressed soft agar colony growth of mouse astrocyte cell lines at low doses (Fig. 3.8d) 
verifying the specific anti-tumor effects of LY3009120 on RAF1 fusion expressing cell lines.  
LY3009120 induces RAF1 fusion homodimerization and heterodimerization with B/CRAF 
but prevents QKI heterodimerization 
To further evaluate the inhibitory mechanism of LY3009120 in RAF1 fusions, we performed 
drug co-IP assays as before. Treatment with 10μM of LY3009120 induced QKI-RAF1 
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homodimers and QKI-RAF1/BRAF heterodimers (Fig. 3.8e) with minimal effect on QKI-
RAF1/CRAF heterodimers. Interestingly, we observed complete disruption of QKI-RAF1/full-
length QKI heterodimerization in the presence of LY3009120 but interaction with N-terminal 
truncated QKI is retained (Fig. 3.8e). These results suggest that while LY3009120 induces and 
stabilizes QKI-RAF1 homo-dimers and hetero-dimers with other RAF proteins, it suppresses the 
RAF1 kinase domains and prevents downstream MAPK/PI3K signaling (Fig. 3.8a, c). However, 
LY3009120 disrupts interaction of full length QKI via some unknown mechanism suggesting that 
LY3009120 can inhibit QKI dimerization residues in QKI-RAF1, subsequently decreasing QKI-
RAF1 dimerization and downstream MAPK/PI3K signaling. The unique ability of dimer inhibitor 
LY3009120 to suppress RAF1 fusions, where existing RAF inhibitors (PLX4720 and PLX8394) 
fail, could be used as a therapeutic option that warrants more testing.  
RAF1 fusions are partially suppressed by MAPK pathway inhibitors in vivo 
Because of the lack of preclinical efficacy of existing RAF inhibitors in RAF1 fusions, we next 
tested effects of clinically available MAPK pathway inhibitors, AZD6244 and trametinib 
(GSK1120212), as single agent therapies against RAF1 fusions. NIH3T3 cell lines over-
expressing QKI-RAF1 and SRGAP3-RAF1 showed a dose dependent decrease in phospho-ERK 
levels with AZD6244 indicating on-target inhibition of MEK1/2 (Fig. 3.9 a, d respectively, left 
panels). In soft agar assays, AZD6244 showed robust growth inhibition against NIH3T3 cells 
expressing QKI-RAF1 and to a lower extent for SRGAP3-RAF1 (Fig. 3.9 b, e respectively, top 
panel, p-value<0.01, 0.1). We also evaluated a more potent MEK inhibitor and FDA approved 
MEK inhibitor, Trametinib. We observed robust decrease in phospho-ERK levels with trametinib 
treatment in NIH3T3 cells expressing QKI-RAF1 and SRGAP3-RAF1 (Fig. 3.9 a, d respectively, 
middle panels) and also in mouse astrocyte cell lines stably transduced with QKI-RAF1 and 
SRGAP3-RAF1 (Fig. 3.9 a, d respectively, right panels). Even low doses of trametinib were 
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successful in inhibiting anchorage independent growth driven by QKI-RAF1 and SRGAP3-RAF1 
in NIH3T3 cells (Fig. 3.9 b, e respectively, top panels, p-value<0.01) and in mouse astrocyte cell 
lines (Fig. 3.9 b, e respectively, bottom panels, p-value<0.01). These in vitro studies suggest that 
trametinib can suppress MAPK signaling and in vitro colony formation driven by RAF1 fusions; 
hence we tested this mono-therapy in vivo.  
We used stable NIH3T3 cell lines expressing RAF1 fusions to form flank xenograft tumors in 
immuno-compromised mice and treated mice daily with trametinib at 1 mg/kg. Despite 
significant activity in vitro, Trametinib mono-therapy only partially suppressed QKI-RAF1 and 
SRGAP3-RAF1 tumor growth (Fig. 3.9 c, d, respectively). The recurrence of tumors in the 
setting of continued trametinib treatment suggests that alternate resistance pathways were 
activated by RAF1 fusions in vivo.  
Combinatorial targeting of MAPK and PI3K/mTOR pathways is more potent in 
suppressing RAF1 fusions than single agent therapies 
Because we observed PI3K/mTOR pathway activation in RAF1 fusion expressing cell lines, we 
sought to test combination therapy targeting both MAPK and PI3K pathways for RAF1 fusions 
using MEK inhibitor trametinib and PI3K/mTOR pathway inhibitor RAD001 (Everolimus). 
NIH3T3 and mouse astrocyte cells expressing QKI-RAF1 (Fig. 3.10a, left and right panel 
respectively) revealed decrease in phospho-ERK and phospho-S6 at very low doses of trametinib 
and 10μM RAD001 indicating targeting of oncogenic signaling. Similar decrease in MAPK and 
PI3K/mTOR signaling was observed in SRGAP3-RAF1 expressing NIH3T3 and mouse astrocyte 
cells (Fig. 3.10c, left and right panel respectively).  
To test the effect of combinatorial treatment on oncogenic growth inhibition in vitro, we 
performed soft agar assays with RAF1 fusion expressing NIH3T3 and mouse astrocyte cells. In 
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both cell model systems, combinatorial targeting was successful at inhibiting anchorage 
independent growth mediated by RAF1 fusions (Fig. 3.10 b, d).  
We then evaluated sensitivity to combinatorial therapy in in vivo models with NIH3T3 flank 
xenografts. As seen in Figure 3.10 e, mice with QKI-RAF1 xenografts treated with single-agent 
RAD001 or trametinib show initial tumor suppression but tumor eventually resurges. QKI-RAF1 
xenograft mice treated with trametinib and RAD001 at 1mg/kg and 10mg/kg, respectively show 
prolonged suppression of tumor growth (Fig. 3.10e). We observed similar responsiveness in 
SRGAP3-RAF1 expressing NIH3T3 flank xenografts, with single-agent therapy against MAPK 
or PI3K/mTOR leading to only partial tumor suppression and combinatorial targeting causing 
more prominent, prolonged tumor regression (Fig. 3.10f). These in vivo results strongly suggest 
the significance of using combinatorial therapy with trametinib and RAD001 for RAF1 fusion 
expressing PLGGs as targeting both signaling pathways would be essential for effective targeted 
therapy.  
Discussion 
In this study, we describe the oncogenic mechanism of action and therapeutic sensitivity of 
PLGG associated RAF1 gene fusions. To our knowledge, this is the first report to distinguish 
between BRAF and CRAF/RAF1 gene fusions, both found in the grade I PLGG, pilocytic 
astrocytomas (PAs) (J. Zhang et al., 2013). While BRAF fusions result in paradoxical activation 
with vemurafenib, a first generation RAF inhibitor, second generation PLX8394 suppresses 
BRAF fusion driven oncogenesis. Interestingly, RAF1 fusions are not suppressed by either 
vemurafenib or PLX8394 but are responsive to novel dimer inhibitor LY3009120 or 
combinatorial targeting with MAPK and PI3K/mTOR pathway inhibitors, highlighting important 
clinical implications. We also report a critical role of the N-terminal fusion partner, QKI in 
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mediating QKI-RAF1 fusion’s oncogenic nature and resistance to existing RAF inhibitors, a 
finding that might be relevant to pan-cancer RAF1 gene fusions. 
The BRAFV600E mutation is found in 6-10% of PAs with other subtypes displaying higher 
incidences (Olow et al., 2016) whereas the KIAA1549-BRAF fusion has been reported in majority 
of PAs, and novel BRAF mutations have also being discovered by deep sequencing (J. Zhang et 
al., 2013). The overall frequency of BRAF mutations is much higher in PAs with a small fraction 
of patients containing RAF1 gene fusions, however their overall prevalence remains unknown. 
Since both RAF1 fusions and BRAF fusions occur in the same PLGG sub-type (J. Zhang et al., 
2013), patients with a clinical diagnosis of PAs might not have the same molecular diagnosis. 
This necessitates development of molecular stratification schemes for PLGGs as patients with 
similar histological diagnosis might have different molecular drivers.  
We found QKI-RAF1 and SRGAP3-RAF1 to be oncogenic proteins in different cellular contexts 
that drive robust in vivo flank xenograft and intra-cranial tumor growth. Relevant patient-derived 
models are extremely rare for PLGGs, with the few reported cell lines not expressing RAF1 
fusions (Bax et al., 2009; Olow et al., 2016). In our model systems, RAF1 fusions were found to 
aberrantly activate both the MAPK and PI3K/mTOR pathways. Despite similar downstream 
signaling to BRAF fusions, RAF1 fusions were found to function differentially and exist as RAF 
inhibitor resistant homodimers and heterodimers with B/CRAF. This is in contrast to KIAA1549-
BRAF fusion that exists solely as homodimers (A. J. Sievert et al., 2013) that we found to be 
disrupted in response to PLX8394. Alternatively, BRAFV600E exists as monomers that are 
targetable by both vemurafenib and PLX8394 (Freeman et al., 2013a; Poulikakos et al., 2011; C. 
Zhang et al., 2015). Differences in response to RAF inhibitor therapy and BRAF mutational 
status has been reported previously but our findings suggest unique differences between BRAF 
and CRAF fusions based on dimerization status, primarily mediated by the non-kinase fusion 
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partner in RAF1 fusions. These mechanistic findings have important implications when assessing 
therapeutic options for patients with RAF1 fusions, as clinically available RAF inhibitors would 
be unsuccessful in disrupting oncogenic dimers of RAF1 fusions, rendering patients resistant to 
therapy. 
LY3009120 is a novel RAF dimer inhibitor drug that has shown promise in inhibiting models 
with various NRAS, KRAS and BRAF mutations (S. H. Chen et al., 2016; Peng et al., 2015). We 
demonstrate ability of LY3009120 to disrupt QKI mediated interaction between QKI-RAF1 
fusions as well as stabilize inactive homodimers and heterodimers with B/CRAF. This strongly 
supports our hypothesis that RAF inhibitor can be effective against RAF1 fusions if would it 
targets dimerization mediated by both fusion partners. Due to distinct binding properties of 
LY3009120, its clinical use could extend from BRAF mutant cancers to RAF1 fusion expressing 
cancers but this would require further in vivo testing.  
The RAS/RAF/MEK signaling cascade is altered in a variety of cancers leading to the successful 
development of potent targeted inhibitors for the downstream kinases, MEK1/2, such as 
Selumetinib (AZD6244) and Trametinib (GSK1120212) (Gilmartin et al., 2011; Henne et al., 
2007; Yamaguchi, Kakefuda, Tajima, Sowa, & Sakai, 2011). While AZD6244 monotherapy has 
been tested against adult cancers (Catalanotti et al., 2013) and is also currently in clinical trial for 
PLGGs (ClinicalTrials.gov Identifier: NCT01089101), we have shown limited response to 
AZD6244 monotherapy in RAF1 fusion expressing cell models. This led us to focus efforts on 
the more potent Trametinib that has also been approved for advanced, refractory melanomas 
(Flaherty et al., 2012). In BRAF mutant cancers, monotherapy with MEK inhibitor is more potent 
than RAF inhibitors but multi-agent therapy combining MEKin with either Vemurafenib or 
mTOR inhibitor (Everolimus) has shown the most promising pre-clinical results (Olow et al., 
2016). In our study, Trametinib monotherapy showed partial suppression of RAF1 fusion driven 
85 
 
tumor growth, highlighting the importance of the parallel PI3K/mTOR pathway in RAF1 fusion 
driven PLGGs. Therefore, we tested combinatorial therapy using MEKin Trametinib and 
mTORin Everolimus (RAD001) and found combinatorial treatment to be most successful at 
prolonged suppression of QKI-RAF1 and SRGAP3-RAF1 driven tumors. This provides a strong 
rationale for clinical use of dual therapy for PLGGs with RAF1 fusion.  Safety and tolerability of 
combining MEK- and mTOR-inhibitors is currently being in adult, advanced cancers 
(ClinicalTrials.gov Identifier: NCT01347866) with pediatric testing in the future (Olow et al., 
2016).  
Most studies on kinase gene fusions have focused on the downstream effects of truncated, 
activated kinases, whereas our study depicts a novel oncogenic role for the non-kinase fusion 
partner. We found that stable dimerization of QKI-RAF1 is mediated by QKI and is essential for 
resistance to RAF inhibitor therapy. This adds to the growing list oncogenic roles being attributed 
to QKI by recent studies including loss of expression/function and altered regulation of target 
RNAs (Abedalthagafi et al., 2015; Bandopadhayay et al., 2016; Conn et al., 2015; Danan-
Gotthold et al., 2015) and its growing importance in regulating brain tumors. However, the role of 
N-terminal fusion partner might be gene-specific, as the ESRP1-RAF1 fusion exists as a 
constitutive dimer where dimerization is mediated by RAF1 and R401H mutation causes loss of 
MAPK signaling (Palanisamy et al., 2010; Yao et al., 2015).  
The distinct sub-types of pediatric low-grade gliomas are beginning to be associated with specific 
mutations such as the association of MYB-QKI with angiocentric gliomas and KIAA1549-BRAF 
fusions with pilocytic astrocytomas but this study adds another layer of complexity with same 
subtype displaying different mutations and distinct therapeutic responses. We highlight the 
importance of molecular classification of PLGGs in assisting targeted therapeutic approaches.  
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Materials and Methods  
Cell Culture: NIH3T3 and HEK 293 cells were obtained from ATCC and maintained in 1X 
DMEM media containing 10% DBS and 10% FBS respectively. We obtained Tp53-null early-
passage primary mouse astrocytes (PMAs) from Suzi Baker’s group at St. Jude Children’s 
Hospital, and these cells were maintained in DMEM- F12 media supplemented with 10% FBS 
and EGF. Cell lines were not re-authenticated and were routinely tested (at least every three 
months) for mycoplasma infection. 
Vector Construction and Generation of Stable Cell Lines: SRGAP3-RAF1 and QKI-RAF1 
constructs were synthesized as Gateway compatible entry clones. Full length RAF1, QKI and 
SRGAP3 plasmids were purchased as gateway entry clones from PlasmID/DF/HCC DNA 
Resource Core. Sub-cloning was done to integrate SRGAP3-RAF1, QKI-RAF1, full-length QKI, 
RAF and SRGAP3 constructs into a Gateway-compatible N-MYC-tagged pMXs-Puro Retroviral 
Vector (Cell Biolabs). Empty MYC-tagged retroviral construct was used as control. Retrovirus 
was generated using Platinum-E retroviral packaging cells (Cell BioLabs) as per manufacturer 
protocols. NIH3T3 cells and early-passage PMAs were transduced with retroviral media for 6 
hours and infected cells were selected with puromycin 48 hours post infection. Stable expression 
of MYC-tagged proteins was confirmed via western blot analysis (anti-MYC HRP 1:5000; 
Invitrogen). For protein-protein interaction assays, we also cloned the above-mentioned 
constructs into Gateway destination vectors with either an N-terminal MYC tag or N-terminal 
FLAG tag (Invitrogen). 
Dimerization mutants of QKI-RAF1 were generated by PCR-based site-directed mutagenesis of 
MYC- and FLAG-tagged constructs described above. RAFR401H dimerization mutants (Freeman et 
al., 2013a, 2013b) in QKI-RAF1 were generated using primers: Forward 
CGCAAAACACACCATGTGAACA and Reverse CAGAACAGCCACCTCATTCCT. QKIE48G 
87 
 
dimerization mutants in QKI-RAF1 were generated using primers: Forward 
CTGGACGAAGGAATTAGCAGAG and Reverse CAGCCGCTCGAGGTGGTT. QKIE48G 
dimerization mutants (T Chen & S Richard, 1998) in QKI-RAF1 were generated using primers: 
Forward CTGGACGAAGGAATTAGCAGAG and Reverse CAGCCGCTCGAGGTGGTT. 
Cellular kinase drug assays: For pathway suppression experiments using RAF inhibitors, 
PLX4720, a first-generation RAF inhibitor, or PLX8394/PB-3, a second-generation paradox-
breaking RAF inhibitor (Plexxikon) or LY3009120, a pan-RAF dimer inhibitor (Eli Lilly; drug 
purchased from Selleck Chemicals) were used at indicated concentrations. The MEK inhibitor, 
GSK1120212 was provided by GlaxoSmithKline, and AZD6244 (Astra Zeneca) was purchased 
from Selleck Chemicals. These drugs were used alone or in combination with RAD001 (mTOR 
inhibitor). All drug aliquots were dissolved in DMSO and stored at −20 °C. Cells were plated at 
1x106 cells/ml in six-well dishes with serum-containing media. Before drug treatment, cells were 
serum starved. Thereafter, cells were exposed to indicated drug concentrations for indicated time 
periods. 
Western Blot Analysis: Stable NIH 3T3 cells and stable PMA cell lines used in drug assays were 
lysed in 1X RIPA (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% 
Nonidet P-40) containing protease and phosphatase inhibitor cocktail (Thermo Fisher). 
Supernatant from centrifuged lysates were normalized for protein concentration using a Pierce 
660nm protein assay and run on NuPAGE precast gels (4–12% Bis-Tris; Life Technologies). For 
MAPK pathway analysis, pMEK, MEK, pERK, ERK antibodies from Cell Signaling were used at 
1:1000 dilutions in BSA. To analyze PI3K/mTOR pathway, pAKT Ser473, pAKT Thr308, AKT, 
pS6, S6 antibodies from Cell Signaling were used.  
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Soft-Agar Cellular Transformation Assays and quantification: Anchorage-independent 
growth of SRGAP3-RAF1 and QKI-RAF1 expressing stable NIH 3T3 cells and PMAs was 
assessed as previously described (Bandopadhayay et al., 2016; Angela J Sievert et al., 2013). 
Images were analyzed using ImageJ and colonies with area greater than 500 pixels quantified. 
Co-immunoprecipitation Assays: Interactions of SRGAP3-RAF1 and QKI-RAF1 with itself, 
wild-type BRAF, CRAF, QKI or SRGAP3 were assessed via co-transfections of MYC- and 
FLAG-tagged constructs into HEK 293 cells using Lipofectamine 2000. Anti-MYC tag antibody 
coated magnetic beads (MBL) were used to immunoprecipitate the transfected proteins from cell 
lysates in 1X RIPA at 4 °C over-night. Beads were washed 3 times for 15 minutes each at 4 °C to 
remove non-specific interactions, followed by a final 1xPBS wash. Proteins were eluted off beads 
using 2xLDS and heating at 70°C for 10 minutes and used for in western blot analysis. Anti-
MYC antibody (Invitrogen, 1:5000) and anti-FLAG antibody (Thermo Fisher, 1:10,000) were 
used to assess co-immunoprecipitation.  
Animal studies: The Children’s Hospital of Philadelphia Institutional Animal Care and Use 
Committee approved all animal protocols. Homozygous NSG strain immuno-deficient mice were 
bred in our animal facility and housed under aseptic conditions. Mice were 6-10 weeks of age, 
with equal representation of male and female mice. 
Mouse flank xenograft studies with NIH3T3 Stable Cell Lines: To assess in vivo tumor growth, 
NIH3T3 cell lines were injected subcutaneously into the flanks of NSG mice (10 mice for each 
cell line, per drug condition) and tumor growth was measured. The GSK1120212 and RAD001 
combinatorial drug study was performed in a xenograft mouse model by pre-treating with daily 
oral gavage (1 mg/kg/dose of GSK1120212 and 10mg/kg of RAD001) for one week prior to 
injecting cell lines subcutaneously into the flanks of NSG mice. Tumor growth was measured 
89 
 
daily while on drug treatment. Ellipsoid tumor volume was calculated using the formula: volume 
= 1/2(length × width2). 
Intracranial mouse injections: 1x106 PMAs expressing SRGAP3-RAF1, QKI-RAF1 and vector 
control were resuspended in Matrigel basement matrix (BD Sciences) and 2 microliter was 
injected stereo-tactically into the right striatum of immuno-compromised NSG mice (5 mice 
each). Animals were monitored and sacrificed at the onset of neurological symptoms, QKI-RAF1 
at day 39 post-injection and SRGAP3-RAF1 at day 42 post-injection. Brains were isolated post 
intra-cardiac perfusion with 4% paraformaldehyde solution and stored in 4% paraformaldehyde 
solution in 1X PBS at 4°C over-night, and subjected to routine histological analysis.  
UV cross-linking and co-immunoprecipitation assays:  To assess the RNA binding capacity of 
QKI in QKI-RAF1, known RNA targets of QKI were used- myelin basic protein (MBP) and  
early growth Response 2 (EGR-2) (Galarneau & Richard, 2005). In vitro transcription of P32 
radiolabeled RNA probes (MBP and EGR-2) and UV cross-linking with QKI or QKI-RAF1 
expressing HEK293 lysates was done as described previously (Lynch & Maniatis, 1996; 
Rothrock, House, & Lynch, 2005). Cross-linked protein-RNA conjugates were immuo-
precipitated using anti-Myc tagged beads and separated on an SDS-PAGE gel.  
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Tables and Figures 
Figure 3.1 
 
Figure 3.1. QKI-RAF1 and SRGAP3-RAF1 are oncogenic via activation of MAPK and PI3K 
pathways. (a) Structure of RAF1 fusions in PLGGs. In QKI-RAF1, exons 1-3 of QKI contain 
QUA1 dimerization domain and a truncated K- homology domain (KH-Tr), and exons 8-17 of 
RAF1 retain the protein kinase domain. In SRGAP3-RAF1, exons 1-10 of SRGAP3 contain the 
Fes/CIP4-Homology (FCH) domain or also called the F-BAR homodimerization domain and, 
RAF1 exons 9-17 encode the RAF1 kinase domain. (b) Table showing different RAF1 fusions 
present in various adult cancers and pediatric cancer. (c) Soft agar assay using NIH3T3 cell lines 
stabling expressing RAF1 fusions. Mean of three measurements is depicted. Error bars represent 
SEM. (d) Western blot analysis of MAPK and PI3K pathway in stable NIH3T3 cell lines under 
serum starvation. (e) Soft agar assay using p53-null mouse astrocyte cells (PMAs) stabling 
expressing RAF1 fusions. Mean of five measurements is depicted. Error bars represent SEM. (f) 
Western blot analysis of MAPK and PI3K pathway in stable PMA cell lines under serum 
starvation. (g) Flank xenograft tumor measurements with stable NIH3T3 cell lines expressing 
RAF1 fusions. Mean of ten measurements is depicted. Error bars represent SEM. (h) Kaplan-
Meier survival plot of NSG mice orthotopically injected with PMAs overexpressing RAF1 
fusions develop tumors with short latency compared to PMAs expressing vector control which 
never developed tumors, n=5, p<0.01. p-value * <0.05, ** <0.01, *** <0.001. 
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Figure 3.2 
 
 
Figure 3.2. Effect of RAF inhibitors on KIAA1549-BRAF signaling. Western blots showing 
paradoxical activation of PLX4720 on growth pathways regulated by KIAA1549-BRAF 
expressing NIH 3T3 cells, PLX8394 can suppress KIAA1549-BRAF signaling. 
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Figure 3.3 
 
 
Figure 3.3. Existing RAF inhibitors do not suppress CRAF fusion driven signaling 
pathways and oncogenic phenotype. Current RAF inhibitors, PLX8394 and PLX4720, have 
minimal effect of on (a) growth pathways and (b) soft agar growth regulated by QKI-RAF1 
expressed in NIH 3T3 cells. Similar unresponsiveness seen on (c) growth pathway and (d) soft 
agars driven by SRGAP3-RAF in NIH 3T3 cells. (e) p53-/- mouse astrocyte cell lines (PMAs) 
with QKI-RAF1 and SRGAP3-RAF1 are unresponsive to current RAF inhibitors. Soft agar 
growth of PMAs expressing (f) QKI-RAF1 and (g) SRGAP3-RAF1 
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Figure 3.4 
 
Figure 3.4. Homo- and hetero-dimerization is required to drive CRAF fusion driven 
gliomagenesis. (a) Co-immunoprecipitation assays show QKI-RAF1 homo-dimerization with 
itself, and hetero-dimerization with wild type BRAF, CRAF and QKI in HEK 293t cells. (b) 
Presence of ‘paradox breaker’ RAF inhibitor, PLX8394, does not affect QKI-RAF1 dimerization 
in co-immunoprecipitation assays in HEK 293t cells. (c) KIAA1549-BRAF homo-dimerization is 
suppressed by PLX8394. 
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Figure 3.5 
 
Figure 3.5. SRGAP3-RAF1 mediated dimerization and oncogenicity is partly mediated 
by RAF1. (a) SRGAP3-RAF1 homo-dimerizes with itself, and hetero-dimerizes with wild type 
BRAF and CRAF. (b) Single dimerization mutants of SRGAP3-RAF1 (RAF1R401H) expressed in 
PMAs show reduction in MAPK pathway. (c) Soft agar assays with SRGAP3- RAF1R401H shows 
decrease in oncogenicity.  
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Figure 3.6 
 
 
Figure 3.6. RAF1 fusions activate oncogenic signaling in a dimerization-dependent 
manner. Co-IP assays using single dimerization mutants of QKI (QKI E48G-RAF1) and RAF1 
(QKI-RAF1R401H) and double dimerization mutants (QKI E48G -RAF1R401H) of QKI-RAF1 against 
(a) QKI-RAF1, (b) BRAF, (c) CRAF/RAF-1 and (d) QKI. PMAs expressing QKI-RAF1 mutants 
were assessed for (e) MAPK and PI3K pathway signaling and (f) soft agar growth. (g) UV 
crosslinking assay with wild type QKI and QKI-RAF1 assessing RNA binding to probes, MBP 
and EGR-2.  
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Figure 3.7 
 
 
Figure 3.7. Expression level of QKI and QKI-RAF1 in UV cross-linking assay.  
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Figure 3.8 
 
Figure 3.8. Novel RAF dimer inhibitor LY3009120 stabilizes and inactivates CRAF fusion 
dimers. Western blot showing suppression of QKI-RAF1 and SRGAP3-RAF1 mediated growth 
pathways in (a) NIH 3T3 cells and (c) PMAs. Soft agar assays showing robust response to 
LY3009120 in (b) NIH 3T3 cells and (d) PMAs. (e) Co-IP assays showing effects of LY3009120 
on QKI-RAF1 dimerization in HEK 293t cells.  
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Figure 3.9 
 
 
Figure 3.9. MEK inhibitors, AZD6244 and GSK1120212, partially suppress QKI-RAF1 
mediated tumor growth. (a) Westerns showing effect of MEK inhibitors on growth pathways 
by QKI-RAF1 in NIH 3T3 cells. (b) MEK inhibitors partially suppress QKI-RAF1 driven soft 
agar growth and mouse flank xenografts. (c)Westerns showing effect of MEK inhibitors on 
growth pathways by SRGAP3-RAF1 in NIH 3T3 cells. (d) MEK inhibitors partially suppress 
SRGAP3-RAF1 driven soft agar growth and mouse flank xenografts. 
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Figure 3.10 
 
Figure 3.10. Combinatorial targeting of MAPK and PI3K pathway (MEK inhibitors+ 
mTOR inhibitors) suppresses CRAF fusion driven tumor growth. (a) Westerns showing effect of 
MEK+ mTOR inhibitors on growth pathways by QKI-RAF1 and SRGAP3-RAF1 in NIH 3T3 
cells. (b) Combination of MEK + mTOR inhibitors robustly suppress CRAF fusion driven soft 
agar growth in NIH 3T3 cells. (c) CRAF fusion driven mouse flank xenografts are suppressed by 
combinatorial targeting of MAPK and PI3K pathways. 
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CHAPTER 4: Discussion 
Takes two to tango: QKI gene fusions define novel oncogenic mechanisms 
driven by both fusion partners 
Rapid advances in deep sequencing technologies and fusion-detection platforms over the past few 
years have raised the total number of pan-cancer gene fusions to be around 10,000 (Latysheva & 
Babu, 2016; Mertens, Johansson, Fioretos, & Mitelman, 2015). The prevalence of gene fusions 
varies widely across adult cancers with the overall frequency of gene fusion being lower than 
occurrence of somatic mutations (Lawrence et al., 2013). But for pediatric brain tumors, 
especially low-grade gliomas, recent studies suggest that genes fusions are the predominant 
pathognomonic events that mediate disease occurrence and progression. Historically, gene 
fusions have mostly been characterized to involve kinases and transcriptional control genes 
(Mitelman, Johansson, & Mertens, 2004) that exert oncogenesis via constitutive activation of 
kinases/signaling pathways or association of a proto-oncogene with a strong promoter, 
respectively. In contrast to these mutually exclusive mechanisms, our studies shed light on novel, 
collaborative processes that gene fusions utilize to drive pediatric brain tumors. Our findings 
show the importance of RNA binding protein QKI as a functional gene fusion partner, 
highlighting an important, understudied role for the non-kinase/non-TF related fusion proteins. 
Furthermore, we highlight how the combination of specific fusion partners in a gene fusion can 
affect not just the pathogenesis and tumor sub-type but also response to targeted therapy.  
MYB-QKI: Synergism of a proto-oncogene and a tumor suppressor  
MYB-QKI is an archetypal example of a gene fusion that is characteristic of a tumor sub-type and 
can be used for diagnostic and molecular subtyping purposes. Our in vitro and in vivo studies 
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show that MYB-QKI is a driver mutation in angiocentric gliomas and mediates gliomagenesis via 
multiple mechanisms (Fig. 4.1). Truncations in MYB result in constitutively active transcriptional 
activity of MYB-QKI, as shown in figure 2.5. Chromosomal rearrangement at 6q results in juxta-
positioning of MYB and QKI, causing association of QKI-related enhancers with MYB promoters 
leading to MYB-QKI expression.  Interestingly, MYB-QKI is capable of driving its own 
expression leading to a unique positive feedback loop. This finding represents a novel mechanism 
utilized by an oncogenic gene fusion and also provides a possible opportunity for epigenetic-
targeted therapies that could possibly block expression of MYB-QKI. Due to lack of patient 
derived lines/models, we could not directly assess if there are any other mechanisms driving the 
MYB promoter, especially since it is inactive in most brain regions.  
In addition to activating the MYB transcriptional axis, MYB-QKI also involves the putative tumor 
suppressor gene QKI. Our findings suggest a strong additive effect due to QKI loss of 
heterozygosity and oncogenic MYB activation in neural stem cells. To our knowledge, this is the 
first demonstration that a proto-oncogene and a tumor suppressor collaborate in a gene fusion 
setting to enhance oncogenesis. From a therapeutic standpoint, these findings suggest that it 
might be insufficient to target only of the fusion partners to get complete efficacy. While no 
approved therapies exist for LOH mutations, epigenetic therapies are emerging as described 
below, and might be useful to target aberrant enhancer driven MYB-QKI expression.  
Overall these findings have broad implications for distinguishing angiocentric gliomas accurately 
from other PLGG sub-types using deep sequencing, RT-PCR or FISH techniques. Other than 
diagnostic benefits, novel targeted therapies can also be designed against MYB-QKI expressing 
AGs, either targeting epigenetic mechanisms mediating fusion expression or target downstream 
pathways driven by MYB-QKI. Furthermore, MYB-QKI can also be used to assess residual 
tumor post-surgery, given tumors express the fusion protein homogenously. Future aims of this 
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project would be to assess therapeutic agents against MYB-QKI, such as JQ1 that is an inhibitor 
of bromodomain-containing protein BRD4 (Filippakopoulos et al., 2010). This is because BRD4 
remains bound to transcriptional start sites of genes (at acetyl-lysine residues) of many genes and 
is also a critical mediator of transcriptional elongation (Yang, 2005) and it has shown therapeutic 
efficacy in castration-resistant prostrate cancer (Asangani et al., 2014). BRD4 inhibition has also 
shown efficacy in suppressing another MYB rearrangement (MYB-NF1b) expressing tumor called 
adenoid cystic carcinoma (ACC) (Y. Drier et al., 2016). JQ1 could prevent MYB-QKI driven 
oncogenic transcriptional program by disrupting the MYB promoter-enhancer loop  but this 
hypothesis needs to be tested.  
QKI-RAF1: Dimerization and activation of kinase mediated by non-kinase partner 
The CRAF fusion, QKI-RAF1, demonstrates another aspect of how QKI can contribute to gene 
fusion biology. Since QKI-RAF1 retains the N-terminal portion of QKI (as compared to C 
terminus in MYB-QKI), QKI homo-dimerization domain is retained along with portion of the 
RBD. This suggested a different mechanism of action for QKI in QKI-RAF1 as opposed to QKI 
LOH and associated loss of tumor suppressor function that we see in MYB-QKI. While loosing 
it’s RNA binding properties in QKI-RAF1 (Fig. 3.6g), QKI supports the oncogenic kinase 
activity of RAF1 via QKI-RAF1 dimerization. We have shown that QKI-mediated dimerization is 
key to maintaining stable QKI-RAF1 homo-dimers and subsequent transformation (Fig. 3.6). 
Future work in this project will assess the cooperativity of QKI loss of functions and QKI-RAF1 
oncogenicity, as we have shown in MYB-QKI tumors.  
RAF1/CRAF has lower basal kinase activity compared to BRAF and requires additional 
phosphorylation/dephosphorylation steps for activation (Dhillon, Meikle, Yazici, Eulitz, & Kolch, 
2002; J. Hu et al., 2013). RAF activation requires phosphorylation at 2 key positions: the C-
terminal activation loop (AL) and the N-terminal acidic NtA) motif (Diaz et al., 1997; Mason et 
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al., 1999). BRAF has acidic residues in the NtA along with constitutively phosphorylated serines 
(SSDD), leaving BRAF in a partially activated state (Mason et al., 1999). RAF1 lacks such 
phosphorylation and needs membrane recruitment and dimerization with BRAF to be activated (J. 
Hu et al., 2013). RAF1 truncations and QKI mediated dimerization might be helping to bypass 
some of these activation steps. This hypothesis needs to be tested further.  
Lastly, our findings highlight the evolving role of CRAF in cancer, in contrast to BRAF being 
considered the RAF protein of choice for oncogenic mutations. Even though BRAF is one of the 
most frequently mutated genes in cancer and is a major focus of targeted therapeutics, this study 
strongly suggests the need to delineate the rare CRAF mutations from BRAF mutations as there 
could be driving distinct molecular mechanisms to activate the MAPK pathway. While 
vemurafenib (PLX4720) doesn’t suppress either BRAF or CRAF fusions in PLGGs, PLX8394 
can target only BRAF fusions but not CRAF fusions (Fig. 3.3). Since both BRAF and CRAF 
fusions occur in pilocytic astrocytomas, our findings point out a key therapeutic distinction with 
differential response to therapy within the same tumor sub-type. While combinatorial targeting 
with a MEK and mTOR inhibitor might be necessary/sufficient for targeting CRAF fusions, it is 
also essential to test upstream RAF targeting options due to evolving resistance mechanisms with 
MAPK targeting (Waanders et al., manuscript under revision with Clinical Cancer Research).  
Overall, QKI-RAF1 is the first RAF fusion in PLGGs where the N-terminal non-kinase partner 
has been shown to be involved in pathogenesis and therapeutic resistance making QKI-RAF1 a 
distinct molecular and therapeutic target (Figure 4.2).  
All about that grade: Molecular stratification of PLGG patients 
Current clinical practice utilizes the WHO classification as the standard of care for PLGGs 
diagnosis, treatment and management (Bergthold et al., 2014) but there is growing consensus that 
histopathological classification is not sufficient to discern between heterogeneous tumor subtypes 
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(Louis et al., 2014). Lack of accurate diagnosis might occur due to significant overlap in 
histologic and clinical features, scare tumor tissue availability, inter-physician variability and 
intra-tumoral heterogeneity (Bergthold et al., 2014). Furthermore, our pre-clinical study suggests 
that histological grade I tumor, PA, would respond differentially to RAF targeted therapy based 
on its mutational profile. Hence, a paradigm shift is impending to integrate traditional 
histopathological PLGG classification with emerging molecular and genomic data, as shown in 
figure 1.4.  
Multiple large-scale sequencing studies have uncovered immense molecular complexity within 
PLGGs. To address this, further work needs to be done to develop comprehensive mutational 
profiles that correlate with histological tumor grades. Furthermore, our study shows that even 
within the same tumor type, distinct molecular entities could exist, requiring even further tumor 
sub-typing. Lastly, application in the clinic would require augmenting current diagnostics with 
deep sequencing technologies so each patient’s tumor can be sequenced and driving mutations 
identified, thereby leading to better clinical outcomes and patient management.  
Rolling in the deep-sequencing: Personalized medicine for PLGG patients 
Despite good overall survival, long-term PLGG survivors suffer from significant morbidities, 
especially when complete surgical resection is difficult due to tumor location, such as in the optic 
pathway, hypothalamus, diencephalon, and brainstem. Therefore, development of novel, 
mutation-specific therapies is essential to deliver less toxic treatments to the developing nervous 
system of young PLGG patients.  
Based on the findings from our study and others, it will become imperative to use deep 
sequencing techniques to first assess the mutational status of PLGG patients before assigning 
therapy. Future work on evaluating the molecular mechanisms of other PLLG-associated gene 
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fusions/mutations will add to the growing body of work for devising mutation-specific targeted 
therapies. Current clinical trials are assessing RAF inhibitors (Dabrafenib, NCT01677741), MEK 
inhibitors (MEK162, NCT02285439; trametinib, NCT02124772 and selumetinib, NCT01089101) 
and mTOR inhibitor (Everolimus, NCT01734512) against children with low-grade gliomas. 
However, future clinical trials should incorporate genomic sequencing to identify patient-specific 
mutations to decide trial eligibility and have maximal efficacy. 
PLGG treatment has evolved from radiation therapy once being the standard-of care to surgery 
and/or chemotherapy being the first line of therapy currently (Bergthold et al., 2014). Radiation 
therapy might still be used in non-surgical, chemotherapy refractory tumors but it can lead to 
severe long-term morbidities as discussed earlier. As such, there is increased awareness that non-
specific therapeutic options should be avoided in treating these children. Our ongoing efforts to 
define the molecular mechanisms driving distinct PLGGs provide hope that there would soon be 
better, less toxic targeted therapies for these clinically challenging childhood tumors.  
Molecular Revolution: Utilizing concepts from PLGG gene fusions to inform 
adult cancers   
Adult LGGs have distinct molecular drivers (for example, IDH1/2 mutations, ATRX mutations 
and 1p/19q co-deletions) and share negligible overlap with the mutation profile of pediatric 
LGGs. In addition to vast differences in the molecular pathogenesis, adult and pediatric brain 
tumors also differ in terms of predilection or tumor site in the brain, cellular microenvironment 
and cell of origin (Baker, Ellison, & Gutmann, 2016).  However, the genes implicated in PLGGs 
are also mutated in several adult cancers, such as the MYB, BRAF, CRAF and QKI genes that 
were under investigation in this study undergo various alterations in adult cancers. Our 
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mechanistic findings have the potential to inform tumor mechanisms in adult cancers that involve 
similar genetic mutations and have shared biology.  
MYB is involved in frequent gene rearrangements, point mutations and deletion events in adult 
cancers. Adenoid cystic carcinoma (ACC), a malignant cancer arising in salivary glands, is 
associated with a hallmark MYB-NF1B fusion event (Ho et al., 2013). Interestingly, a recent study 
has shown that similar to MYB-QKI, the gene rearrangement of MYB-NF1B also results in 
translocation of enhancers close to the MYB promoter, resulting in activation of MYB promoter 
(Y. Drier et al., 2016). Furthermore, MYB-NF1B was also found to bind and activate the MYB 
promoter. These findings suggest that some of our mechanistic findings in MYB-QKI could be 
universally applicable to other adult/pediatric MYB gene rearrangements and other gene fusions 
that involve a proto-oncogene and tumor suppressor gene.  
Our previous studies on therapeutic targeting of BRAF gene fusions have shown similar 
resistance mechanisms to therapy in BRAF mutant melanomas (A. J. Sievert et al., 2013). 
Paradoxical activation of the KIAA1549-BRAF fusion occurred due to vemurafenib therapy, and it 
was later found that BRAFV600E mutant melanomas also exhibit paradoxical activation of 
pathway as a resistance mechanism post initial response. These findings highlight that the basic 
biological mechanisms retain some homogeneity across cancers of different age, cell of origin, 
location, malignancy and prognosis.  Our study on CRAF fusions also holds promise to inform 
therapy for CRAF fusions identified in adult cancers such as prostrate cancer (ESRP1-RAF1, 
AGGF1-RAF1), breast cancer (RAF1-DAZL, CMTM8-RAF1), thyroid cancer (AGGF1-RAF1) and 
pancreatic cancer (HACL1-RAF1) (Fig. 3.1b). While deep sequencing studies have highlighted 
the prevalence of CRAF fusions in several adult cancers, therapeutic targeting for majority of 
these fusions remains unknown. Furthermore, a recent study found a rare CRAF point mutation 
(R391W) as a driver mutation in melanoma where dimerization-dependent oncogenic 
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mechanisms are also at play (Atefi et al., 2016). Therefore, our mechanistic findings on how 
PLGG- associated CRAF fusions display distinct dimerization properties in response to inhibitors 
could be extended to/tested for adult CRAF fusions and mutations, thereby guiding universal 
personalized medicine approaches for all oncogenic CRAF fusions. 
Conclusion  
Overall, our study describes the unique mechanism of action of a new class of gene fusions in 
pediatric low grade gliomas. QKI gene fusions, MYB-QKI and QKI-RAF1 are found to function 
via involvement of both fusion partners thereby opening the field of fusion biology to new 
possibilities. First, we found MYB-QKI to be a single, specific driver event in angiocentric 
gliomas, which have not been associated with a molecular marker thus far. Second, we uncovered 
the oncogenic mechanism of action of MYB-QKI to be a collaboration of gain-of-function of MYB 
oncogene and partial loss of function of QKI tumor suppressor, along with involvement of 
epigenetic events to drive aberrant MYB-QKI expression. Third, our study suggests that QKI-
RAF1 can activate the MAPK and PI3K signaling pathways but they are dependent on QKI-
mediated dimerization, a finding that distinguishes them from other RAF fusions found in 
PLGGs. Lastly, we report differential response to RAF targeted inhibitors in QKI-RAF1 
expressing model systems due to stable dimerization induced by QKI fusion partner. Therefore, 
we have shown how QKI gene fusions function to drive gliomagenesis in PLGGs, with broader 
implications on biological mechanisms adopted by pan-cancer gene fusions and personalized 
medicine approaches for PLGGs.  
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Tables and Figures 
Figure 4.1 
 
Figure 4.1. MYB-QKI drives oncogenesis in angiocentric gliomas via a tripartite 
mechanism. MYB and QKI are located on chromosome 6q and intra-chromosomal deletion 
leads to juxta-positioning of 5’ end of MYB with 3’ end of QKI, causing translocation of 3’UTR 
enhancers. QKI-related enhancers can drive MYB promoter activation, leading to MYB-QKI 
expression. MYB-QKI is oncogenic via additive effects of MYB gain of function and LOH of 
QKI.   
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Figure 4.2 
 
Figure 4.2. MAPK and PI3K oncogenic pathways driven by QKI-RAF1 and response to 
targeted therapies. QKI-RAF1 exists as homodimers and heterodimers (with BRAF, CRAF 
and QKI) that can activate the MAPK/ERK and PI3K/mTOR signaling pathways. While RAF 
inhibitors (PLX4720 and PLX8394) cannot inhibit CRAF fusions, the novel RAF dimer inhibitor 
LY3009120 could be a possible therapeutic option. Combinatorial targeting of downstream 
MAPK and PI3K/mTOR pathways with MEK inhibitor trametinib and mTOR inhibitor 
everolimus, respectively, has shown significant in vitro and in vivo efficacy. 
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